Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 5096. Отображено 200.
05-10-2018 дата публикации

НОВОЕ СОЕДИНЕНИЕ САЛЬВИАНОЛОВОЙ КИСЛОТЫ Т, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ

Номер: RU2668955C2

Изобретение относится к области медицины, в частности к сальвианоловой кислоте T, описанной структурной формулой (I), или ее фармацевтически приемлемой соли, или ее R- или S-изомеру. Изобретение также относится к применению соединения сальвианоловой кислоты Т или ее фармацевтически приемлемой соли или ее R- или S-изомера для антиокислительного действия, для замедления старения или для лечения острого инфаркта миокарда, острой ишемии миокарда или фиброзного заболевания легких. 9 н. и 16 з.п. ф-лы, 22 ил., 13 табл., 4 пр.

Подробнее
10-11-2003 дата публикации

ПРОИЗВОДНЫЕ АМИНОМАСЛЯНОЙ, АМИНОПЕНТАНОВОЙ И АМИНОГЕКСАНОВОЙ КИСЛОТ

Номер: RU2215735C2

Изобретение относится к производным аминомасляной, аминопентановой и аминогексановой кислот общей формулы I где R1 - -COOR10; - (CH2)m-CONHOR10, -CONHNHR10, -(CH2)nSR50 или -Y-P (OR51)2; m = 0, 1, 2; n = 0-3; каждый из R2, R3, R4, R5, R6 и R7 независимо является водородом, С1-8 алкилом, С2-8 алкенилом, -OR11, -SR11, -NR12R13, Циклом 1, С1-8 алкилом, замещенным -OR11, -SR11, -NR12R13, -COR14, гуанидино или Циклом 1, или С2-8 алкенилом, замещенным -OR11, -SR11, -NR12R13, -COR14, гуанидино или Циклом 1, или R3 и R4, взятые вместе, представляют С1-8 алкилен, R5 и R6, взятые вместе, представляют С1-8 алкилен, R3 и R6, взятые вместе, представляют С1-8 алкилен, R2 и R3, взятые вместе, представляют С2-8 алкилен, R4 и R5, взятые вместе, представляют С2-8 алкилен или R6 и R7, взятые вместе, представляют С2-8 алкилен, или (1) R8 представляет собой 1) водород, 2) С1-8 алкил, 3) С1-8 алкоксикарбонил, 4) С1-8 алкил, замещенный -OR26, -SR26, -NR27R28 или -COR29, или 5) С1-8 алкоксикарбонил, замещенный ...

Подробнее
27-04-2007 дата публикации

СПОСОБ ПРЕВРАЩЕНИЯ ЦИС-ТРАНС-СМЕСИ ЗАМЕЩЕННЫХ БЕНЗИЛИДЕНАМИНОВ В ЧИСТЫЙ ЦИС-ИЗОМЕР

Номер: RU2297999C2

Изобретение относится к способу получения чистого цис-изомера из смеси цис-транс-изомеров формулы (I), в которой Ar представляет собой фенил или нафтил, необязательно моно- или дизамещенный C1-5 алкилом, C1-5 алкокси, галогеном, трифторметилом, сложным эфиром или амидо, R представляет собой С1-5 алкил, где указанная формула I включает хиральный атом углерода C1 и смежный хиральный атом углерода С2 и где С2 присоединен к атому водорода и к сильной электрон-акцепторной группе G, выбранной из группы, включающей нитро, нитрозо, нитрил, цианато, изоцианато, нитрозамещенный арил, сульфонил и карбонил и где, по меньшей мере, один атом или группа, присоединенная к C1, отличается от атомов или групп, присоединенных к С2, который может быть использован в качестве промежуточного соединения при синтезе цис-изомеров бензамидпиперидиновых соединений, проявляющих активность в качестве антагонистов NK-1 рецептора. Способ включает стадии диспергирования смеси цис- и транс-изомеров формулы I в инертном растворителе ...

Подробнее
20-11-2012 дата публикации

ПРОЦЕСС ПОЛУЧЕНИЯ СОЕДИНЕНИЙ-ПРЕДШЕСТВЕННИКОВ ДЛЯ РАДИОАКТИВНЫХ ГАЛОГЕНПОМЕЧЕННЫХ СОЕДИНЕНИЙ

Номер: RU2466984C2

Изобретение относится к способу получения соединения -предшественника радиоактивного соединения, помеченного фтором, формулы (2), который включает: стадию взаимодействия, обеспечивающего условия для взаимодействия раствора, содержащего вещество со следующей химической формулой (I): где R1 обозначает защитную группу карбоксильной группы, a R2 - защитную группу аминогруппы вместе с основанием, выбранным из группы, состоящей из алкиламинов, от первичных до четвертичных, с неразветвленной или разветвленной цепью, с 1-10 атомами углерода, азотсодержащих гетероциклических веществ с 2-20 атомами углерода и азотсодержащих гетероароматических веществ с 2-20 атомами углерода, и соединением, реагирующим с ОН-группой соединения с химической формулой (1), с превращением в уходящую группу, выбранным из группы, состоящей из алкилсульфоновой кислоты с неразветвленной или разветвленной цепью из 1-10 атомов углерода, галоалкилсульфоновой кислоты с неразветвленной или разветвленной цепью из 1-9 атомов углерода ...

Подробнее
18-03-2021 дата публикации

ПРОИЗВОДНЫЕ ЭТИНИЛА

Номер: RU2745068C2

Изобретение относится к соединениям формул IA и IB, которые могут найти применение для аллостерического модулирования метаботропного глутаматного рецептора 4 (mGluR4). Изобретение относится также к способу получения соединений IA и IB, к фармацевтической композиции для аллостерического модулирования mGluR4, содержащей эффективное количество соединения формулы IA или IB и фармацевтически приемлемые эксципиенты, и к применению соединения формулы IA или IB для получения лекарственного средства для лечения опосредованных mGluR4 болезни Паркинсона, тревоги, обсессивно-компульсивного расстройства, аутизма, нейропротекции, рака, депрессии и диабета 2 типа. 4 н. и 2 з.п. ф-лы, 2 пр.

Подробнее
24-03-2020 дата публикации

Номер: RU2018131460A3
Автор:
Принадлежит:

Подробнее
10-02-2011 дата публикации

ПРОЦЕСС ПОЛУЧЕНИЯ СОЕДИНЕНИЙ-ПРЕДШЕСТВЕННИКОВ ДЛЯ РАДИОАКТИВНЫХ ГАЛОГЕНПОМЕЧЕННЫХ СОЕДИНЕНИЙ

Номер: RU2009128664A
Принадлежит:

... 1. Способ получения соединения-предшественнника радиоактивного соединения, помеченного фтором, который включает ! стадию взаимодействия, обеспечивающего условия для взаимодействия раствора, содержащего вещество со следующей химической формулой (1) ! ! где R1 обозначает защитную группу карбоксильной группы, а R2 - защитную группу аминогруппы вместе с основанием и соединением, реагирующим с OH-группой соединения с химической формулой (1), при этом защитная группа становится уходящей группой, ! а также ! стадию очистки реакционного раствора, получаемого на стадии взаимодействия, для получения практически индивидуального стереоизомера вещества со следующей химической формулой (2) ! ! где R1 обозначает защитную группу карбоксильной группы, R2 - защитную группу аминогруппы, а R3 - уходящую группу. ! 2. Способ получения по п.1, в котором соединение, реагирующее с OH-группой соединения с химической формулой (1), становящееся уходящей группой на стадии взаимодействия, представляет собой одно или ...

Подробнее
20-01-2010 дата публикации

НОВЫЕ ПОЛИНЕНАСЫЩЕННЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ

Номер: RU2008128318A
Принадлежит:

... 1. Соединение формулы (I) ! ! где R1 представляет собой группу R'1 или -A-R'1, в которой R'1 выбран из -СООН, -COOR3, -CONH2, -CONHR3, -CONR3R4, -СНО, -СН2ОН, -CH2OR5, и А представляет собой линейную или разветвленную С1-С16алкиленовую группу, линейную или разветвленную С2-С16алкениленовую группу или линейную, или разветвленную С2-С16алкиниленовую группу; ! R2 представляет собой ! арильную группу, возможно замещенную, или гетероарильную группу, возможно замещенную, или ! озидный остаток, или ! остаток жирной кислоты, возможно разветвленный и/или замещенный, предпочтительно в конце цепи и, в частности гидрокси, ацетокси или защищенным, или незащищенным амино радикалом, ! группу -ОС-(СН2)n-СО-токоферил (альфа-, бета- или гамма- или дельта-) с 2≤n≤10, ! группу -R'2-О-R6, где R'2 представляет собой ариленовую группу, возможно замещенную, или гетероариленовую группу, возможно замещенную, и R6 представляет собой атом водорода, линейные или разветвленные С1-С16алкильные группы, возможно замещенные ...

Подробнее
15-04-1993 дата публикации

TOPISCHE VORSTUFEN VON ARZNEIMITTELN ZUR BEHANDLUNG VON AKNE UND HAUTKRANKHEITEN.

Номер: DE0003784738D1
Принадлежит: MOLECULAR DESIGN INT

Подробнее
27-10-1994 дата публикации

Process for the preparation of 13-(Z)-retinoic acid

Номер: DE0004313089A1
Принадлежит:

... 13-(Z)-retinoic acid is prepared by a) reaction of 5-hydroxy-4-methyl-2-(5H)-furanone with a [3-methyl-5-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4-pentadienyl] triarylphosphonium salt and b) subsequent partial isomerisation of the mixture of 13-(Z)- and 11,13-di-(Z)-retinoic acid obtained, characterised in that in reaction step a) the reaction is carried out in the presence of lithium hydroxide as alkali metal hydroxide and in dimethylformamide as solvent at temperatures from +10 to -9 DEG C and/or in reaction step b) the isomerisation is carried out by irradiation with light in the wavelength range between 200 and 600 nm of the isomer mixture obtained as in a) in an organic solvent in the presence of a photon sensitiser.

Подробнее
30-06-1971 дата публикации

SYNTHESIS OF alpha,beta-UNSATURATED COMPOUNDS

Номер: GB0001237055A
Автор:
Принадлежит:

... 1,237,055. Ethylenically unsaturated compounds. ZOECON CORP. 17 Oct., 1969 [3 Feb., 1969; 11 April, 1969], No. 51168/69. Heading C2C. ,#-Ethylenically unsaturated compounds are prepared from ,#-acetylenically unsaturated acid esters, amides, aldehydes, ketones or nitriles, having on the #-carbon atom a hydrogen atom or a saturated or unsaturated, substituted hydrocarbon group, by reacting with an organometallic compound. The metal atom of the organo-metallic compound is copper (I), manganese (II), iron (II), cobalt (II), chromium (II) and chromium (III) and the organo group is a saturated or unsaturated, substituted or unsubstituted hydrocarbon group, which is added to the #-carbon atom of the acetylenically unsaturated compound. The organometallic compound may be prepared by reacting (a) a metal salt with organo-lithium; (b) a metal salt with organo-magnesium halide; or metal salt with diorgano-magnesium in an inert anhydrous organic solvent at from - 150‹ C. to room temperature. Examples ...

Подробнее
21-07-1971 дата публикации

CYCLOALIPHATIC UNSATURATED ALCOHOLS

Номер: GB0001240310A
Автор:
Принадлежит:

... 1,240,310. Cycloolefinic unsaturated alcohols. R. FIRMENICH, G. FlRMENICH, R. E. FIRMENICH and F. H. FIRMENICH, [trading as FIRMENICH & CIE.]. 7 Nov., 1968 [9 Nov., 1967; 1 Nov., 1968], No. 3392/71. Divided out of 1,240,309. Heading C2C. The invention comprises compounds of the general formulµ in which the dotted lines represent a double bond in either the 1- or 2-position in the ring. They may be prepared by reacting - or (#-cyclocitral with an organometallic compound of formula ME-CH=CH-CH 3 or ME-C=C-CH 3 , in which ME is a metal function, e.g. Li- or BrMg-, and hydrolysing the product.

Подробнее
21-04-1977 дата публикации

PROSTENOIC ACID DERIVATIVES AND METHOD FOR PREPARING SAME

Номер: GB0001471070A
Автор:
Принадлежит:

... 1471070 Prostaglandins AMERICAN CYANAMID CO 29 April 1974 [11 May 1973] 18749/74 Heading C2C [Also in Division C3] The invention comprises prostaglandins of the Formula A wherein R 1 is C 1-4 alkoxy, #-hydroxy-C 1-4 alkoxy or #-tetrahydropyran-21-yloxy-C 1-4 alkoxy ; R 2 is H, C 1-4 alkyl or triphenylmethyl; R 3 is straight chain C 2-10 alkyl optionally substituted with 1 or 2 C 1-4 alkyl radicals, straight chain C 3-10 alkenylmethyl, optionally substituted by 1 or 2 C 1-4 alkyl radicals, C 4-9 cycloalkyl, C 5-10 alkylcycloalkyl, C 6-12 cycloalkyl-alkyl, in which the cycloalkyl is optionally substituted by a C 1-4 alkyl radical, C 5-9 cycloalkenyl, C 6-10 alkyl-cycloalkenyl, C 6-12 cycloalkenyl-alkyl in which the cycloalkenyl is optionally substituted by a C 1-4 alkyl radical, adamantyl or adamantyl-C 1-4 alkyl; R 4 is OH, C 1-12 alkoxy, C 1-12 alkoxy or 2-tetrahydropyranyloxy; R 3 is H or C 1-3 alkyl; V is >C=O, and Z is -(CH 2 ) n -, -(CH 2 ) n -C(R 5 ) 2 .CH 2 -, -(CH 2 ) n ...

Подробнее
08-07-1970 дата публикации

Process for the preparation of Novel Nickel Alcoholates and the Parent Alcohols thereof

Номер: GB0001197500A
Автор: WILKE G, HEIMBACH P
Принадлежит:

... 1,197,500. Alcohols and nickel alcoholates. STUDIENGESELLSCHAFT KOHLE m.b.H. 17 Oct., 1967 [26 May, 1967], No. 47171/67. Heading C2C. [Also in Division C5] Nickel alcoholates and their parent alcohols are prepared by (a) allowing carbonyl compounds and 1,3-diolefins to react with complexes of nickel (o) or (b) reacting #-allyl nickel compounds with carbonyl compounds and if desired hydrolysing the nickel alcoholate to the parent alcohol. The invention further comprises #-allyl-nickel alcoholates and the following alcohols: octene-(4)-diol-(2,7); 1,6-diphenyl-trans-hexane - (3) - diol - (1,6); 1,10 - diphenyldecatri- 1,5,9 - ene - diol - (3,8); 1,14 - diphenyltetradecapentaene - (1,3,7,11,13) - diol- (5,10); the compound of the formula 2,7 - dimethyloctene - (4) - diol - (2,7); 1,4 - di- (cyclohexanolyl - 1) - butene - (2); 2,7 - diphenyloctene - (4) - diol - (2,7); 1,6 - diphenyl- (3) - methylhexene - (3) - diol - (1,6); 1,6 - diphenyl - (3,4) - dimethylhexene - (3) - diol- (1,6); 1,3,4,6 ...

Подробнее
12-02-1969 дата публикации

Abscisin II

Номер: GB0001142715A
Автор:
Принадлежит:

... 1,142,715. Abscisin II. R. J. REYNOLDS TOBACCO CO. 7 July, 1967 [2 Nov., 1966], No. 31390/67. Heading C2C. 3 - Methyl - 5 - (1 - hydroxy - 4 - oxo - 2,6,6- trimethylcyclohex - 2 - en - 1 - yl) penta - cis - 2, (raws-4-dienoio acid (abscisin II) is prepared by a process which comprises oxidizing a C 1-4 alkyl ester of cis,trans--ionylideneacetic acid with a tertiary alkyl chromate and then hydrolysing the resultant ester. Suitably the oxidation is carried out at 60- 120‹ C. using the methyl or ethyl ester of cis, trans--ionylideneacetic acid. Abscisin II can be separated from its trans, trans isomer by slow crystallization from ether or benzene. -Ionylideneacetic acid is prepared by reacting -ionone with the reaction product of sodium hydride with trimethylphosphonoacetate ...

Подробнее
27-12-2006 дата публикации

Supported ruthenium nanoparticle catalyst for CIS- dihydroxylation and oxidative cleavage of alkenes

Номер: GB0002427404A
Принадлежит:

The present invention relates to the use of nanosized metal particles (e.g., ruthenium) grafted on inert solid support for oxidation of alkenes. The supported metal catalyst can effect cis-dihydroxylation and oxidative cleavage of alkenes to give the respective cis-diols and carbonyl products.

Подробнее
06-02-2002 дата публикации

Chemical process

Номер: GB0000130517D0
Автор:
Принадлежит:

Подробнее
27-04-1983 дата публикации

ISOMERIZATION OF Y-UNSATURATED ALCOHOL OR ITS ESTER

Номер: GB0002054561B
Автор:

Подробнее
09-02-1983 дата публикации

Preparation of esters of 1,5-dimethyl bicyclo (3.2.1) octan-8-ol and the resulting esters

Номер: GB0002102802A
Принадлежит:

Esters of 1,5-dimethyl bicyclo [3.2.1] octan-8-ol are prepared by reacting 1,5-dimethyl-1,5-cyclooctadiene with an essentially inorganic sulphur- or phosphorus-containing polybasic acid and salts thereof are formed by neutralizing said esters. Such esters and salts are novel products. 1,5- Dimethyl bicyclo [3.2.1] octan-8-ol is prepared by heat treatment of the mono- or disulphate in the presence of an acid.

Подробнее
26-01-1983 дата публикации

2-(cyclohexyl)ethyl-cyclohexylnitriles and their use in liquid crystal compositions

Номер: GB0002102000A
Принадлежит:

Compounds of the formula wherein R<1> signifies a straight-chain alkyl group containing 1 to 12 carbon atoms, are especially valuable as components of nematic and cholestric liquid crystal mixtures with positive anisotropy of the dielectric constants and are used for electro- optical purposes.

Подробнее
01-01-1970 дата публикации

Isomerization of Vitamin A Compounds

Номер: GB0001176244A
Автор:
Принадлежит:

... 1,176,244. Isomerizing Vitamin A compounds. CHAS. PFIZER & CO. Inc. 17 May, 1967 [8 Nov., 1966], No. 22987/67. Addition to 1,053,574. Heading C2V. Isomers of Vitamin A, and esters thereof, of low biological activity, namely 9 cis, 9, 13dicis, 11cis and 11, 13di-cis isomers, are converted to mixtures of increased activity, mainly Vitamin A and neo-Vitamin A, and esters thereof, by reaction with iodine and a basic amine at 0‹ to 115‹ C. in an inert solvent. The basic amine may be used as a solvent. The iodine may be removed from the reaction mixture with a reducing agent, preferably an alkali metal borohydride. The reaction with the iodine and basic amine also improves the colour, odour and stability of the products of subsequent esterification or transesterification of Vitamin A compounds. In examples, Vitamin A acetate isomers are reacted with iodine and pyridine, the iodine being reduced with sodium borohydride.

Подробнее
10-07-1944 дата публикации

Improved production of alcohols and/or esters

Номер: GB0000562609A
Автор:
Принадлежит:

Saturated alcohols and esters are obtained by hydrogenating without a catalyst a saturated carboxylate of lead, cadmium or copper, or an unsaturated carboxylate of copper. When a hydroxy-carboxylate is used, the product is a dihydric alcohol or its ester. Carboxylates of several metals, at least one of which is lead cadmium or copper, may be used and result in different yields and different relative proportions of alcohols and esters. The other metals mentioned are chromium, cobalt, nickel, zinc, manganese and iron. Examples describe the reduction with hydrogen of the lead salts of coconut oil acids, copper oleate and lead acetate. Reference has been directed by the Comptroller to Specification 484,995.

Подробнее
12-09-1973 дата публикации

METHOD OF AND COMPOSITION FOR STABILIZING TRANSDIETHYLSTIBESTROL IN ANIMAL FEED RATIONS

Номер: GB0001329547A
Автор:
Принадлежит:

... 1329547 Stilbestrol in animal feed ELI LILLY & CO 14 Jan 1971 [13 Feb 1970 (2)] 27119/72 Divided out of 1329546 Heading A5B A process designed to inhibit isomerization of trans-diethyl stilbestrol in animal feed compositions comprises depositing trans-diethyl stilbestrol from a non-halogenated liquid vehicle on to an inert particulate carrier which is substantially free of solvents for diethyl stilbestrol. The vehicle may be acetone or a C 1-3 alcohol, e.g. ethanol. The carrier may be magnesium, calcium or aluminium silicate bearing mineral, e.g. hydrobiotite, or attapulgite clay, diatomaceous earth, a carbonate, chloride, phosphate or sulphate of Na, K, Mg or Ca, e.g. NaCl, CaCO 3 or dicalcium phosphate ground corn cobs, sugar cane bagasse, dried molasses, beet pulp, corn grits, steamed solvent-extracted bone meal, dried pea bulls, dried potato pulp or polished rice. The product of the invention may be incorporated into an animal feed comprising yellow corn, corn cobs, alfalfa meal, soyabean ...

Подробнее
29-09-1982 дата публикации

SYNTHESISING PREGN-16-ENES FROM 17-KETO-STEROIDS

Номер: GB0002022590B
Автор:
Принадлежит: UPJOHN CO

Подробнее
31-03-2016 дата публикации

COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS

Номер: AP2016009079A0
Автор: DUGGAN KAREN ANNETTE
Принадлежит:

Подробнее
30-06-2003 дата публикации

Guanidinobenzamides as MC4-R agonists

Номер: AP2003002755A0
Принадлежит:

Compounds of formula (IA) and (IB) arc new where the variables R1 through R10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type Tl diabetes, and may be provided as pharmaceutical formulations in conjunction with a pliarmaceutically acceptable carrier- ...

Подробнее
31-10-2009 дата публикации

Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands

Номер: AP2009004970A0
Принадлежит:

Подробнее
30-06-2003 дата публикации

Guanidinobenzamides as mc4-r agonists

Номер: AP0200302755A0
Автор:
Принадлежит:

Подробнее
30-06-2003 дата публикации

Guanidinobenzamides as mc4-r agonists

Номер: AP0200302755D0
Автор:
Принадлежит:

Подробнее
15-05-1982 дата публикации

VERFAHREN ZUR HERSTELLUNG VON NEUER 4-(3-(3(2-(1-HYDROXYCYCLOHEXYL)-AETHYL)-4-OXO-2THIAZOLIDINYL)-PROPYL)-BENZOES[URE

Номер: ATA766078A
Автор:
Принадлежит:

Подробнее
15-05-2010 дата публикации

CATALYST SYSTEM AND PROCEDURE FOR THE RELOCATION FROM EPOXIDEN TO ALLYL ALCOHOLS

Номер: AT0000466829T
Принадлежит:

Подробнее
15-05-2009 дата публикации

PROCEDURE FOR THE PRODUCTION OF MAKROCYCLI KETONE

Номер: AT0000428680T
Принадлежит:

Подробнее
15-04-1976 дата публикации

VERFAHREN ZUR HERSTELLUNG VON ALPHA,BETA-UNGESATTIGTEN ALKOHOLEN AUS DEN ENTSPRECHENDEN ALPHA,BETA-UNGESATTIGTEN ALDEHYDEN

Номер: ATA230974A
Автор:
Принадлежит:

Подробнее
15-06-1980 дата публикации

VERFAHREN ZUR HERSTELLUNG VON VITAMIN K1

Номер: ATA548976A
Автор:
Принадлежит:

Подробнее
15-10-1981 дата публикации

PROCEDURE FOR THE PRODUCTION OF NEW RETINOIDEN

Номер: AT0000522979A
Автор:
Принадлежит:

Подробнее
15-01-2005 дата публикации

ALDOL CONDENSATION

Номер: AT0000285392T
Принадлежит:

Подробнее
15-11-2007 дата публикации

RUTHENIUM COMPLEXES OF PHOSPHINAMINOPHOSPHINLIGANDEN

Номер: AT0000378344T
Автор: BOAZ NEIL, BOAZ, NEIL
Принадлежит:

Подробнее
11-06-1979 дата публикации

PROCEDURE FOR THE PHOTOCHEMICAL ISOMERIZATION OF VITAMIN A AND ITS DERIVATIVES

Номер: AT0000350743B
Автор:
Принадлежит:

Подробнее
15-01-2009 дата публикации

PROCEDURE FOR THE PRODUCTION OF 1 (2.2.6 - TRI METHYL CYCLOHEXYL) - HEXAN-3-OL

Номер: AT0000418529T
Принадлежит:

Подробнее
15-09-1990 дата публикации

PROCEDURE FOR THE PRODUCTION OF PERFLUORALKYLALKOHOLEN.

Номер: AT0000055763T
Принадлежит:

Подробнее
15-06-1991 дата публикации

8 (NIEDERALKYL) BICYCLO (4.2.0>OCTANDERIVATE WITH VALUABLE THERAPEUTIC CHARACTERISTICS.

Номер: AT0000063899T
Принадлежит:

Подробнее
15-02-1986 дата публикации

(3.2.0) BICYCLOHEPTANON MORE OXIMAETHER, THE VALUABLE THERAPEUTIC CHARACTERISTICS POSSESSIONS.

Номер: AT0000017849T
Принадлежит:

Подробнее
15-10-1987 дата публикации

ALLYL AMINE MAO INHIBITORS.

Номер: AT0000029875T
Принадлежит:

Подробнее
10-12-1976 дата публикации

PROCEDURE FOR THE PRODUCTION OF ALPHA, BETA UNGESATTIGTEN ALCOHOLS FROM THE APPROPRIATE ALPHA, BETA UNGESATTIGTEN ALDEHYDES

Номер: AT0000333712B
Автор:
Принадлежит:

Подробнее
12-08-1974 дата публикации

Insecticides means

Номер: AT0000316924B
Автор:
Принадлежит:

Подробнее
10-03-1970 дата публикации

Procedure for the production of new nickel alcoholates as well as the alcohols and Triene derived from it

Номер: AT0000279568B
Автор:
Принадлежит:

Подробнее
26-07-1971 дата публикации

Pesticide

Номер: AT0000291674B
Автор:
Принадлежит:

Подробнее
15-12-2003 дата публикации

NEW PROCEDURE FOR THE PRODUCTION OF ALCOHOLS

Номер: AT0000255083T
Принадлежит:

Подробнее
15-04-2001 дата публикации

PROCEDURE FOR the PRODUCTION OF 13-CIS-RETINSÄURE

Номер: AT0000200278T
Принадлежит:

Подробнее
26-10-2017 дата публикации

DNA-PK inhibitors

Номер: AU2017239481A1
Принадлежит: Baldwins Intellectual Property

Abstract N' -Q R1 The present invention relates to compounds of following formula (I) useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders, such as cancer.

Подробнее
03-01-2002 дата публикации

Oxidation of carbon-boron bonds

Номер: AU0005403501A
Принадлежит:

Подробнее
14-04-2016 дата публикации

New salvianolic acid compound T, preparation method therefor, and use thereof

Номер: AU2014314827A1
Принадлежит:

The present abstract relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound.

Подробнее
15-12-2016 дата публикации

Compositions for the treatment of hypertension and/or fibrosis

Номер: AU2014324078B2
Принадлежит: Shelston IP Pty Ltd.

The present invention relates to a novel terphenyl compound and its use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.

Подробнее
03-01-1985 дата публикации

OXIRANEBUTANOIC ACID ESTERS AND INTERMEDIATES IN THEIR PREPARATION

Номер: AU0000541254B2
Принадлежит:

Подробнее
10-08-2006 дата публикации

DNA-binding protein YB-1-containing collagen accumulation inhibitors

Номер: AU0000784975B2
Принадлежит:

Подробнее
02-03-1972 дата публикации

STABILIZATION OF TRANS ISOMER OF DIETHYLSTILBESTROL

Номер: AU0001915470A
Принадлежит:

Подробнее
17-05-1973 дата публикации

NOVEL ODORANTS

Номер: AU0003556571A
Принадлежит:

Подробнее
29-08-2000 дата публикации

Chemical partitioning agents and methods of using same

Номер: AU0003228700A
Принадлежит:

Подробнее
12-06-1986 дата публикации

2-ARYL 3 HALO ALLYL ALCOHOLS

Номер: AU0005180586A
Автор: BEY PHILIPPE, PHILIPPE BEY
Принадлежит:

Подробнее
02-06-2000 дата публикации

ALDOL CONDENSATION

Номер: CA0002351475A1
Автор: KELLY, GORDON JAMES
Принадлежит:

Production of unsaturated aldehydes by the aldol condensation of straight chain aldehydes, e.g. butyraldehyde, by contacting the aldehyde in the vapour phase with a particulate catalyst comprising at least one basic alkali metal compound supported on an inert substrate at a temperature above 175 ~C.

Подробнее
26-04-1983 дата публикации

TRIAZENE COMPOUND, PRODUCTION AND USE THEREOF

Номер: CA0001145280A1
Принадлежит:

Подробнее
26-05-2009 дата публикации

RETINOL DERIVATIVES POTENTIATION OF ACTIVE SUBSTANCES BY MICELLAR PREPARATION

Номер: CA0002445478C
Принадлежит: ARDENIA INVESTMENTS LTD.

This invention relates to novel compounds, capable of potentiating the efficacy of therapeutically active compounds, for example cytotoxic compounds used in the treatment of cancer. The novel compounds have been shown to increase the pharmacological activity of a conventional paclitaxel formulation and to make it possible to manufacture a new formulation of paclitaxel, exhibiting improved solubility, improved storage properties, and increased therapeutic efficacy as shown in the enclosed examples. (Formula I, II, III, IV, V, VI) ...

Подробнее
04-01-2011 дата публикации

PROCESS FOR THE PRODUCTION OF 9-CIS RETINOIC ACID

Номер: CA0002520018C
Принадлежит: F. HOFFMANN-LA ROCHE AG

A new industrially applicable process for the production of 9-(Z)-retinoic acid is described which is characterized by the conversion of an alkali metal salt of 3-methyl-4-oxocrotonic acid with a C15-triphenyl-phosphonium salt. 9- (Z)-retinoic acid is a versatile compound for the treatment of numerous dermatological diseases.

Подробнее
26-01-1993 дата публикации

PROCEDE DE PREPARATION D'ALCOOLS INSATURES

Номер: CA0001313196C
Принадлежит: RHONE POULENC SANTE, RHONE-POULENC SANTE

BREVET D'INVENTION PROCEDE DE PREPARATION D'ALCOOLS INSATURES RHONE-POULENC SANTE Procédé de préparation d'alcools insaturés par hydrogénation d'un composé carbonylé insaturé en présence d'un catalyseur constitué d'un dérivé du ruthénium associé à un ligand soluble dans l'eau ou d'un complexe du ruthénium avec un ligand soluble dans l'eau.

Подробнее
28-12-1982 дата публикации

PROCESS FOR PREPARING ALIPHATIC COMPOUNDS CONTAINING TWO CONJUGATED DOUBLE BONDS CIS-CIS AND CIS-TRANS, AND THE UTILIZATION OF SUCH PROCESS IN A NEW SYNTHESIS OF CIS,TRANS-9,11- TETRADECADIENYL-ACETATE

Номер: CA1138473A
Принадлежит: MONTEDISON SPA, MONTEDISON S.P.A.

A process is disclosecl for preparing aliphatic compounds containing two conjugated double bonds cis-cis or cistrans, characterized ln that a compound of the general formula (I) (in which R is H or an alkyl containing from 1 to 20 carbon atoms, an alkenyl or alkynyl containing from 2 to 20 carbon atoms, a radical containing an ethereal bond or an acetal or ketal group having from 2 to 20 carbon atoms; X is an ester function selected from the class consisting of the acetates, pivaloates, benzoates, mesitoates, or an ethereal function selected from the class consisting of ethoxy, methoxy, 2-tetrahydropyranyloxy groups) is reacted with an alkyl-magnesium halide of the general foxmula: Z - Mg - R1 (II) (in which Z is chlorine, bromine, iodine, and Rl is like R with the exeeption of H) in the presence of a cuprous halide selected from the group comprising CuCl, CuBr and CuI, at temperatures ranging from about +10.degree. to -30.degree.C, in the presence of ethyl ether or tetrahydrofuran ...

Подробнее
25-04-1978 дата публикации

POLYENE COMPOUNDS

Номер: CA1030153A
Автор:
Принадлежит:

Подробнее
29-03-2012 дата публикации

Process for the preparation of cilastatin and sodium salt

Номер: US20120078009A1

An improved process for preparing Cilastatin Sodium including dissolving Cilastatin acid in a solvent using an organic base, adding sodium salt of a week acid and isolating Cilastatin Sodium.

Подробнее
25-10-2012 дата публикации

Process for producing trans-1233zd

Номер: US20120271069A1
Принадлежит: Honeywell International Inc

Trans-1233zd, the trans-isomer of 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd) can be used as blowing agents, solvents, cleaning agents, as well as monomers of macromolecule compounds, and can be prepared through the dehydrochlorination of 1,1,1-trifluoro-3,3-dichloropropane (HCFC-243fa) with the help of a catalyst. The present invention is directed to an integrated process is proposed to produce trans-1233zd from 243fa, which is consisted of the following four major unit operations: (1) Catalytic dehydrochlorination of 243fa into trans/cis-1233zd, (2) HCl recovery, (3) Catalytic isomerization of cis-1233zd into trans-1233zzd, and (4) Isolation of trans-1233zd.

Подробнее
20-12-2012 дата публикации

Purification of cis-1,1,1,4,4,4-hexafluoro-2-butene via extractive distillation

Номер: US20120323054A1
Автор: Jeffrey P. Knapp
Принадлежит: EI Du Pont de Nemours and Co

A process for separating cis-1,1,1,4,4,4-hexafluoro-2-butene from a first mixture comprising cis-1,1,1,4,4,4-hexafluoro-2-butene and at least one chlorofluoroolefin is disclosed. The process involves the steps of contacting said first mixture with at least one extractive agent, to form a second mixture, distilling said second mixture; and recovering cis-1,1,1,4,4,4-hexafluoro-2-butene substantially free of chlorofluoroolefin.

Подробнее
09-05-2013 дата публикации

Ordered mesoporous titanosilicate and the process for the preparation thereof

Номер: US20130116453A1

The invention discloses three-dimensional, ordered, mesoporous titanosilicates wherein the Ti is in a tetrahedral geometry and exclusively substituted for Si in the silica framework. Such titanosilicates find use as catalysts for epoxidation, hydroxylation, C—H bond oxidation, oxidation of sulfides, aminolysis of epoxide and amoximation, with approx. 100% selectivity towards the products.

Подробнее
13-06-2013 дата публикации

Process for cis-1-chloro-3,3,3-trifluoropropene

Номер: US20130150632A1
Принадлежит: Honeywell International Inc

Disclosed is a process for the preparation of cis-1-chloro-3,3,3-trifluoropropene (cis-1233zd) comprising the steps of (a) providing CF 3 CHClCHCl 2 (233da), and (b) treating the 233da with a dechlorinating agent to produce a mixture of compounds including cis-1-chloro-3,3,3-trifluoropropene, preferably wherein the amount of the cis-isomer generated in the reaction is not less than 30%.

Подробнее
29-08-2013 дата публикации

Metathesis Catalysts Containing Onium Groups

Номер: US20130225807A1
Принадлежит: Apeiron Synthesis Sp zoo

Disclosed herein is a general method for the preparation of complexes containing a quaternary onium group in an inert ligand. Some of these complexes may be represented by formula 1: Methods for the preparation of complexes of formula 1, the preparation of intermediates and the use of complexes of formula 1 in metathesis reactions and a method for conducting an olefin metathesis reaction are also described.

Подробнее
13-03-2014 дата публикации

Unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and uses thereof

Номер: US20140073764A1

The present invention relates to unnatural amino acids comprising a cyclooctynyl or trans-cyclooctenyl analog group and having formula (I) or an acid or base addition salt thereof. The invention also relates to the use of said unnatural amino acids, kits and processes for preparation of polypeptides that comprise one or more than one cyclooctynyl or trans-cyclooctenyl analog group. These polypeptides can be covalently modified by in vitro or in vivo reaction with compounds comprising an azide, nitrile oxide, nitrone, diazocarbonyl or 1,2,4,5-tetrazine group.

Подробнее
05-01-2017 дата публикации

METHODS FOR REMOVING HALOGENATED ETHYLENE IMPURITIES IN 2, 3, 3, 3-TETRAFLUOROPROPENE PRODUCT

Номер: US20170001931A1
Принадлежит: HONEYWELL INTERNATIONAL INC.

Disclosed is a composition comprised of at least one compound selected from 2,3,3,3-tetrafluoropropene, 1,3,3,3-tetrafluoro-1-propene and 1-chloro-3,3,3-trifluoropropene and halogenated impurity selected from the group consisting of HFO-1141 (CH═CHF), HCFO-1140 (CH═CHCl), and HCFO-1131 (CH═CFCl and/or trans/cis-CHF═CHCl) and combination thereof, said halogenated impurity being present in said composition in an amount of 50 ppm or less. 1. A composition comprised of at least one compound selected from 2 ,3 ,3 ,3-tetrafluoropropene , 1 ,3 ,3 ,3-tetrafluoro-1-propene and 1-chloro-3 ,3 ,3-trifluoropropene and halogenated impurity selected from the group consisting of HFO-1141 (CH═CHF) , HCFO-1140 (CH═CHCl) , and HCFO-1131 (CH═CFCl and/or trans/cis-CHF═CHCl) and combination thereof , said halogenated impurity being present in said composition in an amount of 50 ppm or less.2. The composition according to wherein said halogenated impurity is present in said composition in an amount of 20 ppm or less.3. The composition according to wherein said halogenated impurity is present in said composition in an amount of 10 ppm or less.4. The composition according to wherein a second impurity selected from CFCCH claim 1 , HFO-1243zf (CFCH═CH) claim 1 , HFO-1234ze (E/Z-CFCH═CHF) claim 1 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 1 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.5. The composition according to wherein a second impurity selected from CFCCH claim 2 , HFO-1243zf (CFCH═CH) claim 2 , HFO-1234ze (E/Z-CFCH═CHF) claim 2 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 2 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.6. The composition according to wherein a second impurity selected from CFCCH claim 3 , HFO-1243zf (CFCH═CH) claim 3 , HFO-1234ze (E/Z-CFCH═CHF) claim 3 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 3 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.7. The composition according to wherein the second impurity is HFO- ...

Подробнее
02-01-2020 дата публикации

SULFOXIMINE GLYCOSIDASE INHIBITORS

Номер: US20200002326A1
Принадлежит:

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. 3. A mixture comprising compounds Ia and Ib according to claim 2 , having identical groups A claim 2 , R claim 2 , W claim 2 , Q claim 2 , n and m claim 2 , in equal or unequal amounts.4. A compound of formula I according to one of the claim 2 , or claim 2 , wherein R is methyl and/or W is N.11. A compound of formula I according to any one of to claim 2 , wherein m and n simultaneously denote 1.13. A compound of formula (I) according to any one of to for use as a medicament.14. A compound of formula (I) according to any one of to and pharmaceutically usable derivatives claim 2 , solvates claim 2 , salts claim 2 , tautomers claim 2 , enantiomers claim 2 , racemates and stereoisomers thereof claim 2 , including mixtures thereof in all ratios for use in a treatment of a condition selected from neurodegenerative diseases claim 2 , diabetes claim 2 , cancer claim 2 , cardiovascular diseases and stroke.15. A compound for use in a treatment of a condition according to claim 14 , wherein the condition is selected from the group of one or more tauopathies and Alzheimer's disease claim 14 , Dementia claim 14 , Amyotrophic lateral sclerosis (ALS) claim 14 , Amyotrophic lateral sclerosis with cognitive impairment (ALSci) claim 14 , Argyrophilic grain disease claim 14 , Behavioural variant frontomeporal dmenetia (BvFTD) claim 14 , Bluit disease claim 14 , Chronic traumatic encephalopathy claim 14 , Corticobasal degeneration (CBP) claim 14 , Dementia pugilistica claim 14 , Diffuse neurofibrillary tangles with calcification claim 14 , Down's syndrome claim 14 , Familial British dementia claim 14 , Familial Danish dementia claim 14 , Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) claim 14 , Frontotemporal lobar degeneration (FTLD) claim 14 , Ganglioglioma claim 14 , ...

Подробнее
14-01-2021 дата публикации

Method for the isomerization of a 3-(z)-unsaturated carboxylic acid to the 3-(e)-isomer

Номер: US20210009495A1
Принадлежит: BASF SE

The present invention relates to a method for isomerizing a 3-(Z)-unsaturated carboxylic acid of the formula 1-Z or a salt thereof, wherein R 2 is C 1 -C 24 -alkyl, C 2 -C 24 -alkenyl having 1, 2, 3 or more than 3 C—C double bonds, unsubstituted or substituted C 5 -C 12 -cycloalkyl, or unsubstituted or substituted aryl; R 1 is hydrogen or has one of the definitions specified for R 2 ; with the proviso that R 2 has a higher priority than R 1 in accordance with IUPAC; to give a 3-(E)-unsaturated carboxylic acid of the formula I-E or a salt thereof, wherein the isomerization of the compound of the formula 1-Z is effected in the presence of an anhydride of an organic acid and a base or in the presence of a ketene of formula CR 11 R 12 C(0), wherein R 11 and R 12 are as defined in the claims and in the specification and a base. In particular, the present invention relates to a method for preparing compositions with increased content of (3E,7E)-homofarnesylic acid starting from compositions comprising (3Z,7E)- and (3E,7E)-homofarnesylic acid.

Подробнее
03-02-2022 дата публикации

PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS

Номер: US20220032280A1
Принадлежит:

In one aspect, the invention provides a method for synthesizing a fatty olefin derivative. The method includes: a) contacting an olefin according to Formula I 110-. (canceled)13. The method of claim 12 , wherein the unsaturated fatty alcohol is the fatty olefin derivative.14. The method of claim 13 , wherein Ris methyl claim 13 , subscript y is 7 claim 13 , and subscript z is 3.16. The method of claim 15 , wherein Ris methyl claim 15 , subscript y is 7 claim 15 , subscript z is 3 claim 15 , and Ris acetyl.19. The method of claim 18 , wherein Ris H claim 18 , Ris methyl claim 18 , subscript y is 7 claim 18 , and subscript z is 3.21. The method of claim 20 , wherein:{'sup': '7a', 'Ris selected from the group consisting of alkyl, alkoxy, heteroalkyl, aryl, aryloxy, and heteroaryl, each of which is optionally substituted; and'}{'sup': '8a', 'X is O or S and Ris optionally substituted aryl; or'}{'sup': 8a', '12a', '13a', '14a, 'X is O and Ris CRRR.'}22. The method of claim 20 , wherein{'sup': '3a', 'Ris selected from the group consisting of 2,6-dimethylphenyl; 2,6-diisopropylphenyl;'}2,6-dichlorophenyl; and adamant-1-yl;{'sup': '4a', 'sub': 3', '2', '6', '5', '3', '3, 'Ris selected from the group consisting of —C(CH)CHand —C(CH);'}{'sup': '5a', 'Ris H;'}{'sup': '7a', 'Ris selected from the group consisting of pyrrol-1-yl; 2,5-dimethyl-pyrrol-1-yl; triphenylsilyloxy; triisopropylsilyloxy; 2-phenyl-1,1,1,3,3,3-hexafluoro-prop-2-yloxy; 2-methyl-1,1,1,3,3,3-hexafluoro-prop-2-yloxy; 9-phenyl-fluorene-9-yloxy; 2,6-diphenyl-phenoxy; and t-butyloxy; and'}{'sup': 8a', '8a, 'Ris R—X—, wherein'}X═O and{'sup': '8a', 'Ris phenyl which bears two substituents in the ortho positions with respect to O, or which bears at least three substituents, from which two substituents are in the ortho positions with respect to O and one substituent is in the para position with respect to O; or'}{'sup': '8a', 'Ris selected from the group consisting of optionally substituted 8-(naphthalene-1-yl)- ...

Подробнее
17-01-2019 дата публикации

SYSTEMS AND METHODS FOR MANUFACTURING AND SEPARATING (Z)-1-CHLORO-3,3,3-TRIFLUOROPROPENE

Номер: US20190016652A1
Принадлежит:

The present disclosure includes various manufacturing and separation processes for the production of (Z)-1-chloro-3,3,3-trifluoropropene from (E)-1-chloro-3,3,3-trifluoropropene. The efficient separation of (Z)-1-chloro-3,3,3-trifluoropropene from unreacted (E)-1-chloro-3,3,3-trifluoropropene may allow for the ability to recycle unreacted starting materials and to maximize raw material utilization and product yields. 1. A method of manufacturing (Z)-1-chloro-3 ,3 ,3-trifluoropropene comprising:contacting a reactant fluid stream containing (E)-1-chloro-3,3,3-trifluoropropene with a catalyst to form a reacted fluid stream comprising (Z)-1-chloro-3,3,3-trifluoropropene;contacting the reacted fluid stream with a scrubbing fluid to remove a byproduct from the reacted fluid stream;removing the scrubbing fluid from the reacted fluid stream;separating (Z)-1-chloro-3,3,3-trifluoropropene from unreacted (E)-1-chloro-3,3,3-trifluoropropene in the reacted fluid stream; andrecycling the unreacted (E)-1-chloro-3,3,3-trifluoropropene with the reactant fluid stream containing (E)-1-chloro-3,3,3-trifluoropropene.2. The method of claim 1 , wherein the separating (Z)-1-chloro-3 claim 1 ,3 claim 1 ,3-trifluoropropene from unreacted (E)-1-chloro-3 claim 1 ,3 claim 1 ,3-trifluoropropene in the reacted fluid stream is done by distillation.3. The method of claim 2 , wherein the distillation is done with a plurality of distillation columns.4. The methods of claim 3 , wherein the distillation columns are in series.5. The method of claim 1 , wherein the scrubbing fluid comprises water claim 1 , a low-caustic composition claim 1 , or a mixture thereof.6. The method of claim 1 , wherein the dryer comprises a desiccant.7. The method of claim 1 , wherein the dryer comprises molecular sieves claim 1 , a mesoporous material claim 1 , a macroporous material claim 1 , inorganic anhydrites claim 1 , or a combination thereof.8. The method of claim 1 , wherein the catalyst is a high-temperature catalyst ...

Подробнее
28-01-2016 дата публикации

Process for Preparing C3-6(Hydro)Fluoroalkenes by Dehydrohalogenating C3-6 Halo(Hydro)Fluoroalkanes in the Presence of a Zinc/Chromia Catalyst

Номер: US20160023970A1
Принадлежит: MEXICHEM AMANCO HOLDING S.A. DE C.V.

The invention relates to a process for preparing a C3-6 (hydro)fluoroalkene comprising dehydrohalogenating a C3-6 hydro(halo)fluoroalkane in the presence of a zinc/chromia catalyst, wherein the C3-6 (hydro)fluoroalkene produced is isomerised in the presence of the zinc/chromia catalyst. 1. A process for preparing 2 ,3 ,3 ,3-tetrafluoropropene (CF3CF═CH2) comprising:(i) fluorinating 3,3,3-trifluoro-2-chloropropene (CF3CCl═CH2) with HF to produce an intermediate composition comprising 1,1,1,2-tetrafluoro-2-chloropropane (CF3CFClCH3); and(ii) dehydrochlorinating the CF3CFClCH3 in the intermediate composition to produce CF3CF═CH2.2. A process according to claim 1 , wherein step (i) and/or (ii) is carried out in the presence of a catalyst.3. A process according to claim 2 , wherein step (i) is carried out in the presence of a chromia-containing catalyst.4. A process according to claim 2 , wherein step (ii) is carried out in the presence of a zinc/chromia catalyst.5. A process according to claim 4 , wherein the zinc/chromia catalyst comprises 0.01 to 25% by weight zinc.6. A process according to claim 4 , wherein the zinc/chromia catalyst is amorphous or from 0.1 to 50% by weight of the catalyst is in the form of one or more crystalline compounds of chromium and/or one or more crystalline compounds of zinc.7. A process according to claim 1 , wherein the intermediate composition further comprises 1 claim 1 ,1 claim 1 ,1 claim 1 ,2 claim 1 ,2-pentafluoropropene (CF3CF2CH2).8. A process according to claim 7 , wherein CF3CFClCH3 is fluorinated to produce CF3CF2CH3.9. A process according to claim 8 , wherein CF3CFClCH3 is fluorinated with HF in the presence of a chromia-containing catalyst to produce CF3CF2CH3.10. A process according to claim 7 , wherein the CF3CF2CH3 is dehydrofluorinated to produce CF3CF═CH2.11. A process according to claim 1 , wherein the ratio of HF:organics in the fluorinating step is from about 5:1 to about 30:1.12. A process according to claim 1 , ...

Подробнее
28-01-2016 дата публикации

Process for Preparing C3-6 (Hydro)Fluoroalkenes by Dehydrohalogenating C3-6 Halo(Hydro)Fluoroalkanes in the Presence of a Zinc/Chromia Catalyst

Номер: US20160023971A1
Принадлежит: MEXICHEM AMANCO HOLDING S.A. DE C.V.

The invention relates to a process for preparing a C3-6 (hydro)fluoroalkene comprising dehydrohalogenating a C3-6 hydro(halo)fluoroalkane in the presence of a zinc/chromia catalyst, wherein the C3-6 (hydro)fluoroalkene produced is isomerised in the presence of the zinc/chromia catalyst. 1. A fluid comprising an isomer or an isomer blend of a C3-6 (hydro)fluoroalkene , wherein the C3-6 (hydro)fluoroalkene is produced by a process comprising dehydrohalogenating a C3-6 hydro(halo)fluoroalkene in the presence of a zinc/chromia catalyst , wherein the C3-6 (hydro)fluoroalkene produced is isomerised in the presence of the zinc/chromia catalyst.2. A fluid according to claim 1 , wherein the C3-6 (hydro)fluoroalkene exists in E and Z isomers claim 1 , and the ratio of E and Z isomers is changed in the presence of the zinc/chromia catalyst.3. A fluid according to claim 4 , wherein the presence of the zinc/chromia catalyst changes the ratio of E and Z isomers from that which is the kinematic determined mixture of isomers from the preparation of the C3-6 (hydro)fluoroalkene.4. A fluid according to claim 2 , wherein the desired isomer of the C3-6 (hydro)fluoroalkene is recovered in a subsequent step.5. A fluid according to claim 1 , wherein the process is carried out at a temperature of from −70° C. to 400° C. and a pressure of from 0 to 30 bara.6. A fluid according to claim 7 , wherein the process is carried out in the vapour phase at a temperature of from 200 to 360° C.7. A fluid according to claim 5 , wherein the process is carried out at super-atmospheric pressure.8. A fluid according to claim 1 , wherein the C3-6 (hydro)fluoroalkene is a (hydro)fluoropropene and the process comprises dehydrohalogenating a hydro(halo)fluoropropene.9. A fluid according to claim 10 , wherein the (hydro)fluoropropene produced is selected from tetrafluoropropenes and pentafluoropropenes.10. A fluid according to claim 11 , wherein the (hydro)fluoropropene comprises 1 claim 11 ,2 claim 11 ,3 claim ...

Подробнее
26-01-2017 дата публикации

SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF

Номер: US20170022184A1
Принадлежит:

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): 2. The compound of claim 1 , wherein B is cycloalkyl claim 1 , heterocyclyl or heteroaryl.3. The compound of claim 1 , wherein Lis alkylene or absent.7. The compound of claim 4 , wherein Ris alkylcarbonyl claim 4 , aminocarbonyl claim 4 , alkylcarbonylaminyl claim 4 , aminocarbonylaminyl or heteroarylcarbonyl.8. The compound of claim 7 , wherein alkylcarbonyl is substituted with aminocarbonyl claim 7 , hydroxylaminocarbonyl claim 7 , hydroxyl or amino.1029-. (canceled)30. The compound of claim 1 , wherein B is oxo.34. The compound of claim 1 , wherein Ris aryl.35. The compound of claim 34 , wherein Ris phenyl or naphthyl.36. (canceled)37. The compound of claim 34 , wherein Ris substituted with one or more substituents.38. The compound of claim 37 , wherein Ris substituted with halo claim 37 , amino claim 37 , hydroxyl claim 37 , C-Calkyl claim 37 , C-Calkenyl claim 37 , C-Calkynyl claim 37 , cyano claim 37 , C-Chaloalkyl claim 37 , C-Calkoxy claim 37 , alkylaminyl claim 37 , cycloalkyl claim 37 , heterocyclylalkyl claim 37 , heterocyclylalkoxy claim 37 , heterocyclylaminyl claim 37 , cycloalkylaminyl claim 37 , aryl claim 37 , heteroaryl claim 37 , phosphate claim 37 , phosphoalkoxy claim 37 , boronic acid claim 37 , boronic acid ester claim 37 , —OC(═O)R or C-Calkylcarbonyloxy claim 37 , or combinations thereof claim 37 , wherein R is C-Calkyl.39. The compound of claim 38 , wherein le is substituted with fluoro claim 38 , chloro claim 38 , cyclopropyl claim 38 , cyclobutyl claim 38 , hydroxyl claim 38 , amino claim 38 , methyl claim 38 , ethyl claim 38 , isopropyl claim 38 , trifluoromethyl or methoxy claim 38 , or combinations thereof.41. The compound of claim 1 , wherein Ris heteroaryl.43. The compound of claim 1 , wherein Ris H.44. The compound of claim 1 , wherein Rand Rare each independently halo claim 1 , haloalkyl claim 1 , alkyl ...

Подробнее
26-01-2017 дата публикации

Catalysts for (e)-selective olefin metathesis

Номер: US20170022231A1

This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, and the use of such catalysts in the metathesis of olefins and olefin compounds, more particularly, in the use of such catalysts in (E)-selective olefin metathesis reactions. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry.

Подробнее
25-01-2018 дата публикации

PROCESS FOR PREPARATION OF OSPEMIFENE

Номер: US20180022674A1
Принадлежит:

The present invention relates to a process for the preparation of ospemifene and pharmaceutically acceptable salts thereof which comprises the step of recycling the undesired E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol to generate an isomeric mixture of Z,E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol. 2. The process of claim 1 , wherein the desired Z-isomer claim 1 , the compound of formula IIa claim 1 , or a salt thereof is separated from the undesired E-isomer claim 1 , the compound of formula IIb claim 1 , or a salt thereof by a process comprising:(i) subjecting the isomeric mixture of Z,E-4-(4-hydroxy-1,2-diphenylbut-1-enyl)phenol to treatment with a base in a solvent to generate a reaction mixture;(ii) separating the desired Z-isomer, the compound of formula IIa, or a salt thereof and the undesired E-isomer, the compound of formula IIb, or a salt thereof from the reaction mixture obtained in step (i); and(iii) optionally, treating the separated Z-isomer, the compound of formula IIa, or a salt thereof and the E-isomer, the compound of formula IIb, or a salt thereof with an acid.3. The process of claim 2 , wherein the desired Z-isomer claim 2 , the compound of formula IIa claim 2 , or a salt thereof and the undesired E-isomer claim 2 , the compound of formula IIb claim 2 , or a salt thereof are separated from the reaction mixture obtained in step (i) claim 2 , by any of the following:(x) by carrying out step (i) in a solvent in which one of the isomers, or salt thereof is soluble and the other isomer, or salt thereof is insoluble and precipitates out; or(y) by carrying out step (i) in a solvent and by adding an anti-solvent to it wherein one of the isomers, or salt thereof is precipitated out; or(z) by removing the solvent of step (i) and adding a second solvent to it in which one of the isomers, or salt thereof is soluble and the other isomer, or salt thereof is insoluble and precipitates out.4. The process of claim 3 , wherein the solvent in step (x) is ...

Подробнее
10-02-2022 дата публикации

(3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole

Номер: US20220041569A1
Принадлежит: Givaudan SA

The compound (3aS,4aR,5S,7aS,9R,9aR)-2,2,5,8,8,9a-hexamethyloctahydro-4H-4a,9-methanoazuleno[5,6-d][1,3]dioxole, compositions and consumer products comprising the compound, methods of making the compound, and the various uses of the compound.

Подробнее
11-02-2016 дата публикации

Method for producing 3,4-dihydroisoquinoline derivatives and production intermediates of same

Номер: US20160039786A1
Принадлежит: Mitsui Chemicals Agro Inc

Provided are an efficient method for producing 3,4-dihydroisoquinoline derivatives and useful production intermediates thereof. Provided is a method for producing 3,4-dihydroisoquinoline derivatives represented by general formula (1), comprising converting a compound represented by general formula (3) in the presence of acid after reacting with an aniline derivative, or converting a compound represented by general formula (3) by reacting with an aniline derivative in the presence of an acid.

Подробнее
14-02-2019 дата публикации

METHOD FOR CO-PRODUCTION OF 1-CHLORO-3,3,3-TRIFLUOROPROPENE, 2,3,3,3-TETRAFLUOROPROPENE AND 1,3,3,3-TETRAFLUOROPROPENE

Номер: US20190047925A1
Принадлежит:

This invention discloses a method for co-production of 1-chloro-3,3,3-trifluoropropene, 2,3,3,3-tetrafluoropropene and 1,3,3,3-tetrafluoropropene. This method includes inputting the mixed gases of hydrogen fluoride and 1,1,1,3,3-pentachloropropane together with 1,1,2,3-tetrachloropropene into a first reactor for a reaction to obtain a reaction product; directly inputting the reaction product into a second reactor to perform a reaction in the presence of a catalyst; separating hydrogen chloride from the obtained product; obtaining 1-chloro-3,3,3-trifluoropropene, 2,3,3,3-tetrafluoropropene and 1,3,3,3-tetrafluoropropene respectively after water washing, alkaline washing, drying and rectifying. This invention has the advantages of flexible production, simple process, small investment, low energy consumption and high conversion rate. 17-. (canceled)8. A method for co-production of 1-chloro-3 ,3 ,3-trifluoropropene , 2 ,3 ,3 ,3-tetrafluoropropene and 1 ,3 ,3 ,3-tetrafluoropropene , the method comprising:{'sup': '−1', '(a) preheating and then directing hydrogen fluoride and 1,1,1,3,3-pentachloropropane into a first reactor in a molar ratio of 9:1-15:1, wherein the first reactor comprises an upper section filled with an aluminum oxide supported chromium metal catalyst and a lower section filled with a chromic oxide supported indium metal catalyst, wherein the hydrogen fluoride and the 1,1,1,3,3-pentachloropropane are reacted in the upper section of the first reactor at a temperature of 200-400° C. and at an air flow rate of 300-1,000 h, and a product from the upper section enters the lower section of the first reactor to continuously react with the 1,1,2,3-tetrachloropropane to obtain a first reaction product of the first reactor, wherein a molar ratio of the 1,1,2,3-tetrachloropropane to the hydrogen fluoride in the lower section of the first reactor is 3:9-5:9;'}{'sup': '−1', '(b) directly directing the first reaction product of the first reactor into a second reactor ...

Подробнее
14-02-2019 дата публикации

METHODS FOR REMOVING HALOGENATED ETHYLENE IMPURITIES IN 2, 3, 3, 3-TETRAFLUOROPROPENE PRODUCT

Номер: US20190047927A1
Принадлежит: HONEYWELL INTERNATIONAL INC.

Disclosed is a composition comprised of at least one compound selected from 2,3,3,3-tetrafluoropropene, 1,3,3,3-tetrafluoro-1-propene and 1-chloro-3,3,3-trifluoropropene and halogenated impurity selected from the group consisting of HFO-1141 (CH═CHF), HCFO-1140 (CH═CHCl), and HCFO-1131 (CH═CFCl and/or translcis-CHF═CHCl) and combination thereof, said halogenated impurity being present in said composition in an amount of 50 ppm or less. 1. A composition comprised of 2 ,3 ,3 ,3-tetrafluoropropene and a halogenated impurity comprising CH═CFCl , said halogenated impurity being present in said composition in an amount greater than 0 ppm and less than or equal to 50 ppm , wherein 2 ,3 ,3 ,3-tetrafluoropropene is present in said composition in at least 90% by weight.2. The composition according to wherein the hydrogenated impurity is present in said composition in an amount greater than 0 ppm but less than or equal to 20 ppm.3. The composition according to wherein the halogenated impurity is present in said composition in an amount greater than 0 ppm but less than or equal 10 ppm.4. The composition according to wherein one or more compounds selected from CFC□CH claim 1 , HFO-1243zf (CFCH═CH) claim 1 , HFO-1234ze (E/Z-CFCH═CHF) claim 1 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 1 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.5. The composition according to wherein a compound selected from CFC≡CH claim 2 , HFO-1243zf (CFCH═CH) claim 2 , HFO-1234ze (E/Z-CFCH═CHF) claim 2 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 2 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.6. The composition according to wherein a compound selected from CFC≡CH claim 3 , HFO-1243zf (CFCH═CH) claim 3 , HFO-1234ze (E/Z-CFCH═CHF) claim 3 , HCFO-1233zd (E/Z-CFCH═CHCl) claim 3 , HCFO-1233xf (CFCCl═CH) and combination thereof is additionally present.7. The composition according to wherein the compound is HFO-1243zf (CFCH═CH) claim 6 , HFO-1234ze (E/Z-CFCH═CHF) claim 6 , or ...

Подробнее
14-02-2019 дата публикации

TRANS-ISOMERIC HETEROCYCLIC COMPOUNDS AND PREPARATION THEREOF

Номер: US20190047956A1
Принадлежит:

A trans-isomeric compound of formula (I) below or a pharmaceutically acceptable salt thereof: 2. The compound of claim 1 , wherein Ris C-Calkyl.3. The compound of claim 2 , wherein Ris methyl.8. The method of claim b claim 2 , wherein Ris C-Calkyl.9. The method of claim 8 , wherein Ris methyl.10. The method of claim 6 , wherein the palladium catalyst is Pd(OH)/C claim 6 , Pd/C claim 6 , Pd(OAc) claim 6 , Pd/AlO claim 6 , or a combination thereof claim 6 , optionally containing Pt/C or Rh/C; and the content of palladium in the palladium catalyst is 0.01 wt % to 30 wt %.11. The method of claim 6 , wherein the inert solvent is HO claim 6 , a C-Cester claim 6 , a C-Ccycloalkane claim 6 , tetrahydrofuran (THF) claim 6 , dimethylformamide (DMF) claim 6 , acetonitrile claim 6 , a C-Calcohol claim 6 , an alkylene glycol monoalkyl ether claim 6 , an alkylene glycol monoalkyl ether carboxylate claim 6 , an amide-based solvent claim 6 , an organic acid claim 6 , or a combination thereof claim 6 , optionally combined with one or more inorganic acids.12. The method of claim 11 , wherein the inert solvent is HO claim 11 , a C-Cester claim 11 , a C-Ccycloalkane claim 11 , THF claim 11 , DMF claim 11 , a C-Calcohol claim 11 , propylene glycol monomethyl ether claim 11 , propylene glycol monomethyl ether acetate claim 11 , N claim 11 ,N-dimethylacetamide claim 11 , a C-Ccarboxylic acid claim 11 , a C-Csulfonic acid claim 11 , or a combination thereof claim 11 , optionally combined with hydrochloric acid.13. The method of claim 12 , wherein the inert solvent is HO claim 12 , methanol claim 12 , ethanol claim 12 , isopropanol claim 12 , formic acid claim 12 , acetic acid claim 12 , ethyl acetate claim 12 , methanesulfonic acid claim 12 , or a combination thereof claim 12 , optionally combined with hydrochloric acid.14. The method of claim 11 , wherein the inert solvent is an organic acid or a combination of the organic acid with one or more solvents selected from the group consisting ...

Подробнее
27-02-2020 дата публикации

Process for preparing (e2,z6)-2,6-nonadienal

Номер: US20200062682A1
Принадлежит: Shin Etsu Chemical Co Ltd

The object of the present invention is to provide an industrial and economical process for preparing (E2,Z6)-2,6-nonadienal of the following formula (4): The present invention provides a process for preparing (E2,Z6)-2,6-nonadienal (4), comprising at least steps of: subjecting (Z3,Z6)-3,6-nonadien-1-ol of the following formula (1): to oxidation with a sulfoxide compound of the following formula (2): CH 3 (R′)S═O  ( 2 ) in which R 1 represents a monovalent hydrocarbon group having from 1 to 12 carbon atoms, in the presence of a sulfur trioxide complex and an amine compound of the following formula (3): N(R 2 )(R 3 )(R 4 )  ( 3 ) in which R 2 , R 3 , and R 4 each independently represent a monovalent hydrocarbon group having from 1 to 12 carbon atoms, or R 3 and R 4 may be bonded to each other to form a divalent hydrocarbon group having from 3 to 12 carbon atoms, R 3 -R 4 , to form the aforesaid (E2,Z6)-2,6-nonadienal (4).

Подробнее
27-02-2020 дата публикации

MODULATORS OF ROR-GAMMA

Номер: US20200062707A1
Принадлежит:

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders. 125-. (canceled)28. The compound of claim 27 , wherein Lis CH claim 27 , CH(CH) claim 27 , O claim 27 , or C(═O).30. The compound of claim 29 , wherein Ris hydrogen claim 29 , (C-C)alkyl claim 29 , hydroxy(C-C)alkyl claim 29 , —(C-C)alkylNH claim 29 , —(C-C)alkyl-N-di(C-C)alkyl claim 29 , or —(C-C)alkoxy-C(O)—NH; and Ris hydrogen.31. The compound of claim 30 , wherein Ris hydroxy(C-C)alkyl.32. The compound of claim 31 , wherein Ris (C-C)alkyl or cyclopropyl.33. The compound of claim 32 , wherein Cyis aryl or heteroaryl claim 32 , each substituted with 1 to 3 groups independently selected from R.34. The compound of claim 33 , wherein Cyis phenyl or pyridyl claim 33 , each substituted with 1 to 3 groups independently selected from R.35. The compound claim 34 , wherein at least 1 Ris S(O)(C-C)alkyl.36. The compound of claim 35 , wherein Cyis pyridyl substituted with 1 to 3 groups independently selected from R claim 35 , wherein at least 1 Ris S(O)(C-C)alkyl.37. The compound of claim 35 , wherein Cyis phenyl claim 35 , pyridyl claim 35 , cyclohexyl claim 35 , tetrahydropyranyl claim 35 , cyclopropyl claim 35 , or cyclobutyl claim 35 , each optionally substituted with 1 to 3 groups independently selected from R.38. The compound of claim 37 , wherein Cyis phenyl claim 37 , pyridyl claim 37 , cyclohexyl claim 37 , or tetrahydropyranyl claim 37 , each optionally substituted with 1 to 3 groups independently selected from R.39. The compound of claim 38 , wherein Cyis phenyl or cyclohexyl claim 38 , each optionally substituted with 1 to 3 groups independently selected ...

Подробнее
27-02-2020 дата публикации

PROCESS FOR PREPARING BTK INHIBITORS

Номер: US20200062762A1
Принадлежит: Genentech, Inc.

Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided. 2. The method of claim 1 , wherein the volume to weight ratio of the solvent system to compound 170 in the reaction mixture is from about 5:1 to about 20:1 liters per kg.3. The method of claim 1 , wherein:{'sub': 3', '4, 'the base in the first reaction mixture is KPO, and the solvent system in the first reaction mixture comprises water and a polar aprotic solvent, wherein the volume ratio of water to polar aprotic solvent is from about 0.1:1 to about 0.4:1.'}4. The method of claim 1 , wherein:the yield of compound 190 is at least 80%, and the purity of compound 190 is at least 99 area %.6. The method of claim 5 , wherein the ratio of the solvent volume to compound 160 weight in the reaction mixture is from about 5:1 to about 15:1 liters per kg claim 5 , and wherein the equivalent ratio of catalyst to compound 160 is from about 0.01:1 to about 0.03:1.7. The method of claim 6 , wherein the catalyst is Pd(OAc) claim 6 , the ligand is DPPF claim 6 , the base is potassium carbonate claim 6 , and the polar aprotic solvent is tetrahydrofuran.89-. (canceled)11. The method of claim 10 , wherein the reaction mixture comprises: a ratio of solvent volume to compound 180 weight of from about 5:1 to about 20:1 liters to kg; an equivalent ratio of borylation reagent to compound 180 of between 1 and 2; an equivalent ratio of palladium catalyst to compound 180 of from 0.001:1 to about 0.005:1; an equivalent ratio of catalyst ligand to catalyst of from about 1.5:1 to about 3; and an equivalent ratio of potassium acetate to compound 180 of greater than 1:1.13. The method of wherein the catalyst ligand is XPhos. ...

Подробнее
11-03-2021 дата публикации

FLUOROOLEFIN PRODUCTION METHOD

Номер: US20210070678A1
Принадлежит: DAIKIN INDUSTRIES, LTD.

The present disclosure provides a method for producing fluoroolefin represented by formula (1): CXX═CXX, wherein X, X, X, and Xare the same or different, and represent a hydrogen atom or a fluorine atom, with high selectivity. Specifically, the present disclosure is a method for producing fluoroolefin represented by formula (1), wherein the method includes the step of performing dehydrofluorination by bringing a fluorocarbon represented by formula (2): CXXFCXXH, wherein X, X, X, and Xare as defined above, into contact with a base, and the dehydrofluorination step is performed in the liquid phase at a temperature of −70° C. or higher to less than 120° C. 1. A method for producing a fluoroolefin represented by formula (1): CXX═CXX , wherein X , X , X , and Xare the same or different , and represent a hydrogen atom or a fluorine atom ,{'sup': 1', '2', '3', '4', '1', '2', '3', '4, 'the method comprising a step of performing dehydrofluorination by bringing a fluorocarbon represented by formula (2): CXXFCXXH, wherein X, X, X, and Xare as defined above, into contact with a base,'}the dehydrofluorination step being performed in the liquid phase at a temperature of −70° C. or higher to less than 120° C.2. The production method according to claim 1 , wherein the fluoroolefin represented by formula (1) is at least one member selected from the group consisting of 1 claim 1 ,2-difluoroethylene (HFO-1132) claim 1 , 1 claim 1 ,1-difluoroethylene (HFO-1132a) claim 1 , and trifluoroethylene (HFO-1123).3. The production method according to claim 1 , wherein the fluorocarbon represented by formula (2) is at least one member selected from the group consisting of 1 claim 1 ,1 claim 1 ,1-trifluoroethane (HFC-143a) claim 1 , 1 claim 1 ,1 claim 1 ,2-trifluoroethane (HFC-143) claim 1 , 1 claim 1 ,1 claim 1 ,2 claim 1 ,2-tetrafluoroethane (HFC-134) claim 1 , and 1 claim 1 ,1 claim 1 ,1 claim 1 ,2-tetrafluoroethane (HFC-134a).4. The production method according to claim 1 , wherein the base is ...

Подробнее
24-03-2022 дата публикации

Method for producing difluoroethylene

Номер: US20220089512A1
Принадлежит: Daikin Industries Ltd

Provided is a method for efficiently obtaining HFC-1132(E) and/or HFO-1132(Z). The method includes supplying a composition containing HFO-1132(E) and/or HFO-1132(Z) to a reactor to perform isomerization between HFO-1132(E) and HFO-1132(Z) by irradiating the composition with light.

Подробнее
16-03-2017 дата публикации

CLOMIPHENE SYNTHESIS USING A SINGLE SOLVENT

Номер: US20170073302A1
Принадлежит: REPROS THERAPEUTICS INC.

The present invention provides a one-pot method for synthesizing clomiphene (a mixture of the isomers cis-clomiphene and trans-clomiphene) utilizing a single solvent. In a preferred embodiment, the single solvent is dichloromethane (DCM, also known as methylene chloride). The present invention provides an improved method for synthesizing clomiphene and purifying clomiphene isomers. 2. The method of claim 1 , wherein the solvent is dichloromethane.3. The method of wherein the mineral acid in step (a) is sulfuric acid.4. The method of claim 1 , wherein the chlorinating agent in step (b) is N-chlorosuccinimide.5. The method of claim 3 , wherein the solution is maintained at a temperature of about 0° C. during addition of the mineral acid in step (a).6. The method of wherein a suitable base is added to the clomiphene solution obtained in step (b) thereby converting clomiphene to the free base form.7. The method of claim 6 , wherein saturated aqueous sodium bicarbonate solution is added to the clomiphene solution obtained in step (b).8. The method of claim 6 , comprising loading the solution comprising clomiphene free base onto a chromatographic column and eluting the column under conditions suitable for obtaining essentially pure trans-clomiphene.9. The method of further comprising recrystallizing the trans-clomiphene.10. A method for preparing essentially pure trans-clomiphene isomer comprising dissolving a desired quantity of 1-{4-[2-(Diethylamino)ethoxy]phenyl}-1 claim 8 ,2-diphenylethanol in a suitable amount of dichloromethane and thereafter(a) adding to the dichloromethane solution a mineral acid in an amount effective to dehydrate the 1-{4-[2-(Diethylamino)ethoxy]phenyl}-1,2-diphenylethanol thereby producing a 2-{4-[(Z)-1,2-diphenylvinyl]phenoxy}-N,N-di ethyl ethanaminium salt; and thereafter(b) adding to the dichloromethane solution N-chlorosuccinimide in an amount effective to chlorinate the 2-{4-[(Z)-1,2-diphenylvinyl]phenoxy}-N,N-diethyl ethanaminium salt ...

Подробнее
18-03-2021 дата публикации

PROCESS FOR PREPARING BTK INHIBITORS

Номер: US20210079004A1
Принадлежит: Genentech, Inc.

Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided. 2. The method of wherein the volume to weight ratio of the solvent system to compound 170 in the reaction mixture is from about 5:1 to about 20:1 liters per kg claim 1 , or about 10:1 liters per kg claim 1 , and the equivalent ratio of compound 181 to compound 170 is greater than 1:1 claim 1 , and the equivalent ratio of the palladium catalyst to compound 170 is from about 0.005:1 to about 0.02:1 claim 1 , or about 0.01:1.4. The method of wherein:the yield of compound 190 is at least 60%, at least 70%, at least 80% or at least 90%, and the purity of compound 190 is at least 99 area % or at least 99.5 area %; andthe yield of compound 200 is at least 60%, at least 70%, at least 80%, or at least 85%, and the purity of compound 200 is at least 99 area % or at least 99.5 area %.6. The method of wherein the ratio of the solvent volume to compound 160 weight in the reaction mixture is from about 5:1 to about 20:1 liters per kg claim 5 , from about 5:1 to about 15:1 liters per kg claim 5 , or about 10:1 liters per kg claim 5 , and wherein the equivalent ratio of catalyst to compound 160 is from about 0.01:1 to about 0.03:1.7. The method of wherein the catalyst is Pd(OAc) claim 6 , the ligand is DPPF claim 6 , the base is potassium carbonate claim 6 , and the solvent is tetrahydrofuran.9. The method of wherein the polar aprotic solvent is THF; the mole ratio of n-butyl lithium to compound 95 is between 1:1 and 2:1 claim 8 , or from about 1.2:1 to about 1.6:1; the first reaction mixture and the second reaction mixture are formed at a temperature of greater than −35° C.; of the solvent volume to ...

Подробнее
22-03-2018 дата публикации

New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof

Номер: US20180079707A1
Автор: Thibaud Portal
Принадлежит: Galderma Research and Development SNC

The invention relates to new compounds of the general formula (I): as well as the use thereof in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, in particular), or in the use of cosmetic compositions.

Подробнее
30-03-2017 дата публикации

Hydroformylation catalyst

Номер: US20170087542A1
Принадлежит: Eastman Chemical Co

This invention pertains to hydroformylation catalysts containing a mixture of isomeric forms of halo-phosphorus ligands. This invention also describes a procedure for preparing isomers of certain halophosphite ligands, which contain the phosphorus atom in a macrocyclic ring.

Подробнее
05-05-2022 дата публикации

OLEFIN ISOMERIZATION WITH SMALL CRYSTALLITE ZEOLITE CATALYST

Номер: US20220135499A1
Принадлежит: Lyondell Chemical Technology, L.P.

A skeletal isomerization process for isomerizing olefins is described. The process includes the steps of feeding an olefin-containing feed to a reactor having an isomerization catalyst with a small crystalline size that is less than 1 μm in all directions. The small crystalline size increases the life of the catalyst and the yield of skeletal isomer products, as well as reducing the formation of heavy C5+ olefin byproducts, as compared to processes using conventional catalyst with crystalline sizes of 1 μm or more.

Подробнее
05-05-2022 дата публикации

METHOD OF IMPROVING OLEFIN ISOMERIZATION

Номер: US20220135500A1
Принадлежит: Lyondell Chemical Technology, L.P.

A skeletal isomerization process for isomerizing olefins is described. The process includes the steps of feeding an olefin-containing feed to a reactor at a space velocity of 1-100 hrfor a first period of time at a first temperature, followed by discontinuing, or stopping, the olefin-containing feed for a second period of time while maintaining the reactor at a second temperature, before resuming the flow of the olefin-containing feed for a third period of time. The methods of this disclosure increase the yield of the skeletal isomers product while reducing the production of C5+ heavy olefins. Additionally, the methods of this disclosure can be applied to feeds containing iso-olefins (for the production of linear olefins) or linear olefins (for the production of iso-olefins).

Подробнее
05-04-2018 дата публикации

E-1-CHLORO-3,3,3-TRIFLUOROPROPENE PRODUCTION PROCESS FROM 1,1,3,3-TETRACHLOROPROPENE

Номер: US20180093934A1
Принадлежит: Arkema France

A production process for the production of E-1-chloro-3,3,3-trifluoropropene, the process including at least one stage during which 1,3,3,3-tetrachloropropene reacts with anhydrous hydrofluoric acid in the liquid phase, in the absence of a catalyst, with an HF/1,1,3,3- tetrachloropropene molar ratio between 3 and 20 inclusive, at a temperature between 50° C. and 150° C. inclusive and an absolute pressure of between 1 and 20 bar inclusive. 1. A production process for the production of E-1-chloro-3 ,3 ,3-trifluoropropene , the process comprising at least one stage during which 1 ,3 ,3 ,3- tetrachloropropene reacts with anhydrous hydrofluoric acid in the liquid phase , in the absence of a catalyst , with an HF/1 ,1 ,3 ,3- tetrachloropropene molar ratio between 3 and 20 inclusive , at a temperature between 50° C. and 150° C. inclusive and an absolute pressure of between 1 and 20 bar inclusive.2. A production process for the production of E-1-chloro-3 ,3 ,3-trifluoropropene , the process comprising:(i) at least one stage during which 1,1,3,3-tetrachloropropene reacts with anhydrous hydrofluoric acid in the liquid phase in a reactor equipped with a drain and an effluent outlet;(ii) at least one stage for treating the effluent from the reactor in order to provide a flow A that comprises E-1-chloro-3,3,3-trifluoropropene, HCl, HF and Z-1-chloro-3,3,3-trifluoropropene and a flow B that comprises at least 50% HF in weight;(iii) at least one stage for recovering the hydrochloric acid from flow A, the hydrochloric acid being in flow C and flow D that includes E-1-chloro-3,3,3-trifluoropropene, HCl, HF and Z-1-chloro-3,3,3-trifluoropropene;(iv) at least one stage for purifying flow D from stage (iii) in order to purify the E-1233zd to a level higher than or equal to 98% in weight.3. The production process of claim 2 , the process comprises a drainage stage claim 2 , wherein drainage collected in the reactor drain is claim 2 , after treatment claim 2 , recycled back to the ...

Подробнее
12-04-2018 дата публикации

PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS

Номер: US20180099268A1
Принадлежит: Provivi, Inc.

In one aspect, the invention provides a method for synthesizing a fatty olefin derivative. The method includes: a) contacting an olefin according to Formula I 128-. (canceled)30. The method of claim 29 , wherein subscript y is 7.31. The method of claim 29 , wherein Ris H claim 29 , Ris methyl claim 29 , Ris acetyl claim 29 , subscript y is 7 claim 29 , and subscript z is 3.34. The method of claim 29 , wherein the metathesis catalyst is of the formula LL′AA′M═CRRor LL′AA′M═(C═)CRR claim 29 , whereinM is ruthenium;L and L′ are each independently any neutral electron donor ligand and preferably selected from phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibnite, ether, amine, amide, imine, sulfoxide, carboxyl, nitrosyl, pyridine, thioether, or heterocyclic carbenes; and{'sub': 1', '20', '1', '20', '2', '20', '1', '20', '1', '20', '1', '20', '1', '5', '1', '5', '1', '5', '1', '5, 'A and A′ are anionic ligands independently selected from halogen, hydrogen, C-Calkyl, aryl, C-Calkoxide, aryloxide, C-Calkoxycarbonyl, arylcarboxylate, C-Ccarboxylate, arylsulfonyl, C-Calkylsulfonyl, C-Calkylsulfinyl; each ligand optionally being substituted with C-Calkyl, halogen, C-Calkoxy; or with a phenyl group that is optionally substituted with halogen, C-Calkyl, or C-Calkoxy; and A and A′ together may optionally comprise a bidentate ligand; and'}{'sub': b', 'c', '1', '20', '1', '20', '1', '20', '1', '20', '1', '20', '1', '20', '1', '20', 'b', 'c', '1', '5', '1', '5', '1', '5', '1', '5, 'Rand Rare independently selected from hydrogen, C-Calkyl, aryl, C-Ccarboxylate, C-Calkoxy, aryloxy, C-Calkoxycarbonyl, C-Calkylthio, C-Calkylsulfonyl and C-Calkylsulfinyl, each of Rand Roptionally substituted with C-Calkyl, halogen, C-Calkoxy or with a phenyl group that is optionally substituted with halogen, C-Calkyl, or C-Calkoxy.'}38. The method of claim 37 , wherein the olefin is a linear C-Colefin claim 37 , the metathesis reaction part is a Δ-unsaturated fatty acid ...

Подробнее
08-04-2021 дата публикации

PHARMACEUTICAL COMPOUNDS

Номер: US20210101893A1
Принадлежит:

This invention relates to compounds that are agonists of the muscarinic Mand/or Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula 5. The compound according to claim 1 , wherein Ris methyl claim 1 , ethyl or methylcyclobutyl.6. The compound according to claim 1 , wherein Ris methylcyclobutyl.7. The compound according to claim 1 , wherein Ris H claim 1 , methyl claim 1 , ethyl or methylcyclobutyl.8. The compound according to claim 1 , wherein Ris H.11. The compound according to claim 1 , wherein Ris selected from H claim 1 , methyl claim 1 , cyano and F.12. The compound according to claim 1 , wherein Ris H.13. The compound according to claim 1 , wherein Ris methyl claim 1 , trifluoromethyl claim 1 , ethyl claim 1 , isopropyl or cyclopropyl.14. The compound according to which is selected from:N-(1-Methylcyclobutyl)-1-[8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]oct-3-yl]piperidine-4-carboxamide;(1R,5S,6r)-N,N-Diethyl-3-[9-(3-methyl-1,2,4-oxadiazol-5-yl)-3-oxa-9-azabicyclo[3.3.1]non-7-yl]-3-azabicyclo[3.1.0]hexane-6-carboxamide;1-(8-(3-Methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-(trifluoromethyl)cyclobutyl)piperidine-4-carboxamide;N-(1-Ethylcyclobutyl)-1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidine-4-carboxamide;N-(1-isopropylcyclobutyl)-1-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)piperidine-4-carboxamide;1-(8-(3-Methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-methylcyclopentyl)piperidine-4-carboxamide;1-(8-(3-Methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-((1-methylcyclobutyl)methyl)piperidine-4-carboxamide;(1R,5S,6r)-3-(8-(3-methyl-1,2,4-oxadiazol-5-yl)-8-azabicyclo[3.2.1]octan-3-yl)-N-(1-methylcyclobutyl)-3-azabicyclo[3.1.0]hexane-6-carboxamide;N-(1- ...

Подробнее
29-04-2021 дата публикации

METHODS OF MAKING OLEFINIC E- AND Z-ISOMERS

Номер: US20210122697A1
Принадлежит:

Method of making a second olefin using a first olefin, comprising steps (A) and (B): (A) performing a metathesis reaction with the first olefin in the presence of a metal complex configured to catalyse said metathesis reaction; (B) epoxidizing an olefin contained in the reaction mixture obtained in step (A) to form an epoxide; and deoxygenizing said epoxide to form said second olefin. 1. A method of making a second olefin using a first olefin , comprising steps (A) and (B):(A) performing a metathesis reaction with the first olefin in the presence of a metal complex configured to catalyse said metathesis reaction in order to obtain a reaction mixture containing an olefin; and(B) epoxidizing the olefin contained in the reaction mixture obtained in step (A) to form an epoxide; and deoxygenizing said epoxide to form said second olefin.2. The method of claim 1 , wherein the first olefin comprises an E-isomer and a Z-isomer of the olefin.3. The method of claim 2 , wherein the ratio of the E-isomer to the Z-isomer is in the range of from 1:1 to 9:1.4. The method of claim 2 , wherein said second olefin is said Z-isomer claim 2 , further comprising the enrichment of the E-isomer over the Z-isomer claim 2 , and the subsequent conversion of the E-isomer into the Z-isomer to form the second olefin claim 2 , wherein step (A) comprises step (A1):(A1) subjecting the first olefin comprising a mixture of the E-isomer and the Z-isomer to a cross metathesis reaction with a third olefin in the presence of the metal complex, wherein the metal complex is configured to favour reaction of said third olefin with said Z-isomer over the reaction of said third olefin with said E-isomer.5. The method of claim 4 , wherein said third olefin is a Colefin.6. The method of claim 4 , wherein said third olefin is ethylene.7. The method of claim 4 , further comprising conversion of the E-isomer enriched in step (A1) to the Z-isomer claim 4 , the conversion comprising steps (B1) to (B4):(B1) epoxidizing ...

Подробнее
09-06-2022 дата публикации

SULFOXIMINE GLYCOSIDASE INHIBITORS

Номер: US20220177470A1
Принадлежит:

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. 3. A mixture comprising compounds Ia and Ib according to claim 2 , having identical groups A claim 2 , R claim 2 , W claim 2 , Q claim 2 , n and m claim 2 , in equal or unequal amounts.4. The compound of claim 1 , wherein R is methyl and/or W is N.11. The compound of claim 1 , wherein m and n simultaneously denote 1.13. (canceled)14. A method of treating a condition that is a neurodegenerative disease claim 1 , diabetes claim 1 , cancer claim 1 , cardiovascular disease claim 1 , or stroke claim 1 , comprising administering a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically usable derivative claim 1 , solvate claim 1 , salt claim 1 , tautomer claim 1 , enantiomer claim 1 , racemate claim 1 , or stereoisomer thereof claim 1 , including mixtures thereof in all ratios claim 1 , to a mammal in need of such treatment.15. The method of claim 14 , wherein the condition is selected from the group of one or more tauopathies claim 14 , Alzheimer's disease claim 14 , Dementia claim 14 , Amyotrophic lateral sclerosis (ALS) claim 14 , Amyotrophic lateral sclerosis with cognitive impairment (ALSci) claim 14 , Argyrophilic grain disease claim 14 , Behavioural variant frontotemporal dementia (BvFTD) claim 14 , Bluit disease claim 14 , Chronic traumatic encephalopathy claim 14 , Corticobasal degeneration (CBP) claim 14 , Dementia pugilistica claim 14 , Diffuse neurofibrillary tangles with calcification claim 14 , Down's syndrome claim 14 , Familial British dementia claim 14 , Familial Danish dementia claim 14 , Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) claim 14 , Frontotemporal lobar degeneration (FTLD) claim 14 , Ganglioglioma claim 14 , Gangliocytoma claim 14 , Gerstmann-Straussler-Scheinker disease claim 14 , Globular glia tauopathy ...

Подробнее
03-05-2018 дата публикации

BETA-NAPHTHOISOFLAVONES, COMPOSITIONS CONTAINING, AND USES OF, SAME

Номер: US20180118707A1
Принадлежит: Thesan Pharmaceuticals, Inc.

The present invention provides compounds of the following structure, 2. The method of claim 1 , wherein adjacent substituents U claim 1 , V and W and X claim 1 , Y and Z may form a saturated or unsaturated 5-membered or 6-membered carbocyclic or heterocyclic ring.3. The method of . claim 1 , wherein:each of U, V, W, X, Y, and Z is independently:{'sub': 3', '2', '2', '3', '2', '2', '3', '2', '3', '2', '3', '2', '2', '3', '2', '1', '1', '1', '1', '2', '3', '4, 'H; OH; F; Cl; Br; I; CH; CHF; CHF; CF; O-alkyl; O-cycloalkyl; O-alkylcycloalkyl; OCHF; OCHF; OCF; O—(CO)—R; O—(CNH)—R; O—(CN R)—R; SOH or an ester thereof; COH or an ester thereof; POHor a phosphate thereof; PO(OCH)H or a phosphonate thereof; NH; NHCH(O); NRCH(O); NHC(O)R; NRC(O)R; C(O)NRR; C(NH)NRR; C(NH)NROH; or C(NR)NRC(NR)NRR;'}{'sub': 2', '3', '4, 'wherein each of R, 112, R, Rand Rif present is IndependentlyH, OH; optionally substituted alkyl; cycloalkyl; alkylcycloalkyl; heterocycloalkyl; alkylheterocycloalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted aryl; optionally substituted alkylaryl; optionally substituted heteroaryl; or optionally substituted alkylheteroaryl;and wherein A is CH or N.4. The method of claim 2 , wherein:each of U, V, W, X, Y, and Z is independently:{'sub': 3', '2', '2', '3', '2', '2', '3', '1', '3', '2', '3', '2', '2', '3', '2', '1', '1', '1', '1', '2', '3', '4, 'H; OH; F; Cl; Br; I; CH; CHF; CHF; CF; O-alkyl; O-cycloalkyl; O-alkylcycloalkyl; OCHF; OCHF; OCF; O—(CO)—R; O—(CNH)—R; O—(CNR)—R; SOH or an ester thereof; COH or an ester thereof; POHor a phosphate thereof; PO(OCH)H or a phosphonate thereof; NH; NHCH(O); NRCH(O); NHC(O)R; NRC(O)R; C(O)NRR; C(NH)NRR; C(NH)NROH; or C(NR)NRC(NR)NRR;'}{'sub': 1', '2', '3', '4, 'wherein each of R, R, R, Rand Rif present is independentlyH, OH; optionally substituted alkyl; cycloalkyl; alkylcycloalkyl; heterocycloalkyl; alkylheterocycloalkyl; optionally substituted alkenyl; optionally substituted ...

Подробнее
16-04-2020 дата публикации

Series of Compounds for Treatment of Skin Diseases and Other Conditions

Номер: US20200115307A1
Принадлежит: Unigen, Inc.

Compounds and methods related to the prevention and treatment of diseases and conditions, some of which are facilitated by melanogenesis are disclosed. Specifically, the present subject matter includes a series of compounds and compositions and their use for anti-melanogenic and antioxidant activity. This subject matter also includes the treatment of skin disorder due to acne vulgaris and related inflammatory and post inflammatory hyperpigmentation. Methods for synthesizing contemplated compounds are also disclosed. 2. The compound of claim 1 , wherein R is selected from the group consisting of an aromatic or heteroaromatic ring selected from the group consisting of phenyl claim 1 , naphthyl claim 1 , biphenyl claim 1 , 2-pyridyl claim 1 , 3-pyridyl claim 1 , 4-pyridyl claim 1 , 2-furanyl claim 1 , 3-furanyl; wherein R is substituted with 1 to 3 moieties (R′ claim 1 , R″ claim 1 , R′″) independently selected from the group consisting of a C-Calkyl group claim 1 , a C-Calkoxy group or a hydroxyl group.3. The compound of claim 1 , wherein R is selected from the group consisting of 1′-(4′-hydroxy)phenyl; 1′-(3′-hydroxy)phenyl; 1′-(2′ claim 1 ,4′-dihydroxy)phenyl; 1′-(3′ claim 1 ,5′-dihydroxy)phenyl with E and Z geometrical isomer.4. The compound of selected from the group consisting of (E/Z)-4-(2 claim 1 ,6-dimethylhepta-1 claim 1 ,5-dienyl)phenol (1); (E/Z)-3-(2 claim 1 ,6-dimethylhepta-1 claim 1 ,5-dienyl)phenol (2); (E/Z)-4-(2 claim 1 ,6-dimethylhepta-1 claim 1 ,5-dienyl)benzene-1 claim 1 ,3-diol (3); (E/Z)-5-(2 claim 1 ,6-dimethylhepta-1 claim 1 ,5-dienyl)benzene-1 claim 1 ,3-diol (4).6. The compound of claim 5 , wherein R is selected from the group consisting of an aromatic or heteroaromatic ring selected from the group consisting of phenyl claim 5 , naphthyl claim 5 , biphenyl claim 5 , 2-pyridyl claim 5 , 3-pyridyl claim 5 , 4-pyridyl claim 5 , 2-furanyl claim 5 , 3-furanyl; wherein R is substituted with 1 to 3 moieties (R′ claim 5 , R″ claim 5 , R′″) ...

Подробнее
16-04-2020 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20200115359A1
Принадлежит: Haldor Topsoe A/S

New adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and a co-monomer useful for the preparation of polymers and co-polymers. Also, a process of preparing the new adipate-type compounds from bio-based raw materials such as sugars. 2. The compound according to claim 1 , wherein n is 2.3. The compound according to claim 1 , wherein n is 3.5. The process according to claim 4 , wherein n is 2.6. The process according to claim 4 , wherein n is 3.7. The process according to claim 4 , wherein the conversion temperature of iii) is in the range of from 20 to 120° C.8. The process according to claim 4 , wherein step iii) is continued for a period of time in the range of from 5 minutes to 24 hours.9. The process according to claim 4 , wherein the conversion step of iii) is conducted at a pressure in the range of from 1 to 1000 kPa claim 4 , such as from 10 to 125 kPa.10. The process according to claim 4 , wherein the conversion step of iii) is conducted in the presence of a solvent selected from methyl lactate claim 4 , ethyl lactate claim 4 , toluene claim 4 , dichlormethane claim 4 , or mixtures thereof. The present application is a divisional of U.S. application Ser. No. 16/096,103, filed on Oct. 24, 2018, which is a U.S. National Stage of International Application No. PCT/EP2017/060702, filed on May 4, 2017, which claims the benefit of Danish Application No. PA 2016-00273, filed on May 4, 2016. The entire contents of each of U.S. application Ser. No. 16/096,103, International Application No. PCT/EP2017/060702, Danish Application No. PA 2016-00273 are hereby incorporated herein by reference in their entirety.The present invention regards a new compound suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and co-polymers. The invention also regards the ...

Подробнее
16-04-2020 дата публикации

SELECTIVE NR2B ANTAGONISTS

Номер: US20200115370A1
Принадлежит:

The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system. 113-. (canceled)15. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.16. A method for the treatment of depression claim 14 , Alzheimer's disease claim 14 , neuropathic pain claim 14 , or Parkinson's disease claim 14 , which comprises administering to a patient a therapeutically effective amount of a compound of .18. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.19. A method for the treatment of depression claim 17 , Alzheimer's disease claim 17 , neuropathic pain claim 17 , or Parkinson's disease claim 17 , which comprises administering to a patient a therapeutically effective amount of a compound of .21. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.22. A method for the treatment of depression claim 20 , Alzheimer's disease claim 20 , neuropathic pain claim 20 , or Parkinson's disease claim 20 , which comprises administering to a patient a therapeutically effective amount of a compound of .24. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.25. A method for the treatment of depression claim 23 , Alzheimer's disease claim 23 , neuropathic pain claim 23 , or Parkinson's disease claim 23 , which comprises administering to a patient a therapeutically effective amount of a compound of . This application claims the benefit of Indian Provisional Patent Application serial number 3309/DEL/2015 filed Oct. 14, 2015 ...

Подробнее
27-05-2021 дата публикации

Isomerization method of cyclohexane dicarboxylic acid

Номер: US20210155572A1
Принадлежит: Hanwha Solutions Corp

Provided is an isomerization method of cyclohexane dicarboxylic acid using zirconia or titania as an isomerization catalyst.

Подробнее
10-05-2018 дата публикации

Inhibitors of ras and methods of use thereof

Номер: US20180127396A1
Принадлежит: ARAXES PHARMA LLC

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R″, Q, W, X, Y, Z, n 2 and

Подробнее
10-05-2018 дата публикации

ETHYNYL DERIVATIVES

Номер: US20180127429A1
Принадлежит: Hoffmann-La Roche Inc.

The present invention relates to compounds of formula I 3. The compound of formula Ia according to claim 1 , wherein said compound is:(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-(2-methoxyethyl)-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-(3-methoxypropyl)-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-2-(2,2,2-trifluoroethyl)-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione; or,Ethyl 4-[(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-1,6,8-trioxo-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidin-2-yl]butanoate.5. The compound of formula b according to claim 4 , wherein said compound is:(9aRS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-2-(m-tolylmethyl)-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aRS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-2-(p-tolylmethyl)-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aRS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-2-(o-tolylmethyl)-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aRS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-[(2,6-dimethylphenyl)methyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aRS)-2-[(2-chlorophenyl)methyl]-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aRS)-2-[(3-chlorophenyl)methyl]-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-[(2-fluorophenyl)methyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione;(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-[(3-fluorophenyl)methyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione; or,(9aS)-7-[2,6-difluoro-4-(2-phenylethynyl)phenyl]-2-[(4-fluorophenyl)methyl]-9a-methyl-4,9-dihydro-3H-pyrazino[1,2-c]pyrimidine-1,6,8-trione ...

Подробнее
10-05-2018 дата публикации

FLUORO OLEFIN COMPOUNDS USEFUL AS ORGANIC RANKINE CYCLE WORKING FLUIDS

Номер: US20180128131A1
Принадлежит:

Aspects of the present invention are directed to working fluids and their use in processes wherein the working fluids comprise compounds having the structure of formula (I): 1. A process for converting thermal energy to mechanical energy in a Rankine cycle comprising:vaporizing a working fluid with a hot heat source;expanding the resulting vapor and then cooling with a cold heat source to condense the vapor; andpumping the condensed working fluid;wherein the working fluid comprises 1,3,3,3-tetrafluoropropene.2. The process of wherein the working fluid is selected from the group consisting of 1 claim 1 ,3 claim 1 ,3 claim 1 ,3-tetrafluoropropene(E) claim 1 , 1 claim 1 ,3 claim 1 ,3 claim 1 ,3-tetrafluoropropene(Z) and combinations thereof.3. The process of wherein the working fluid comprises a blend of 1 claim 1 ,3 claim 1 ,3 claim 1 ,3-tetrafluoropropene and 2 claim 1 ,3 claim 1 ,3 claim 1 ,3-tetrafluoropropene.4. The process of claim 3 , wherein 1 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene comprises 1 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene(E).5. The process of claim 3 , wherein 2 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from greater than about 0 wt % to about 40 wt. % and 1 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from less than 100 wt. % to about 60 wt. %.6. The process of claim 3 , wherein 2 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from greater than about 0 wt % to about 30 wt. % and 1 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from less than 100 wt. % to about 70 wt. %;7. The process of claim 3 , wherein 2 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from about 5 wt % to about 30 wt. % and 1 claim 3 ,3 claim 3 ,3 claim 3 ,3-tetrafluoropropene is provided in an amount from about 95 wt % to about 70 wt. %.8. The process of claim 3 , wherein 2 claim 3 ,3 claim 3 ,3 claim 3 ...

Подробнее
11-05-2017 дата публикации

Electrochemical isomerization of muconic acid

Номер: US20170129995A1

Various embodiments disclosed relate to electrochemical isomerization of muconic acid. In various embodiments, the present invention provides a method to prepare trans,trans-muconic acid. The method can include passing current through a catalytic cathode in a reactor including an aqueous acidic solution including cis,trans-muconic acid, a supporting electrolyte, and an anode, so as to isomerize the cis,trans-muconic acid to yield a product including trans trans-muconic acid.

Подробнее
17-05-2018 дата публикации

PROCESS FOR ISOLATING AND PURIFYING AMBROX

Номер: US20180134678A1
Автор: Eichhorn Eric
Принадлежит:

A method of isolating and purifying (−)-Ambrox from a reaction mixture comprising (−)-Ambrox and one or more of the compounds (II), (III) and (IV) 2. The method according to comprising the step of selectively crystallizing (−)-Ambrox from a mixture comprising one or more of the compounds (II) claim 1 , (III) or (IV).4. The method according to claim 1 , wherein the reaction mixture is free claim 1 , or is substantially free claim 1 , of homofarnesol.5. The method according to claim 2 , wherein the crystallizing solvent is selected from the group consisting of water claim 2 , methanol claim 2 , acetone claim 2 , petroleum ether claim 2 , hexane claim 2 , t-butyl methyl ether claim 2 , THF and ethyl acetate ethanol claim 2 , toluene and mixtures thereof.6. The method according to claim 5 , wherein the crystallizing solvent is an ethanol water mixture.7. The method according to claim 1 , wherein the reaction mixture is formed as a result of an enzyme-catalyzed cyclization of homofarnesol comprising a mixture of 7E claim 1 ,3E and 7E claim 1 ,3Z homofarnesol geometric isomers of homofarnesol claim 1 , wherein the reaction is carried out in the presence of a recombinant microorganism expressing the gene encoding the enzyme.8. The method according to claim 7 , wherein the reaction mixture of 7E claim 7 ,3E and 7E claim 7 ,3Z homofarnesol is enriched in the 7E claim 7 ,3E geometric isomer.9. The method according to claim 7 , wherein the reaction mixture of 7E claim 7 ,3E and 7E claim 7 ,3Z homofarnesol consists of 7E claim 7 ,3E and 7E claim 7 ,3Z homofarnesol and no other geometric isomers of homofarnesol.10. The method according to claim 7 , wherein the weight ratio of the 7E claim 7 ,3E isomer to 7E claim 7 ,3Z isomer is at least 80:20.11. The method according to claim 7 , wherein the enzyme is a wild-type squalene hopene cyclase or a variant of the wild-type squalene hopene cyclase.13. The perfume ingredient according to claim 12 , comprising crystalline (−)-Ambrox15. ...

Подробнее
17-05-2018 дата публикации

Vinyl Modifier Composition And Processes For Utilizing Such Composition

Номер: US20180134815A1
Принадлежит: BRIDGESTONE CORPORATION

An oxolanyl compound-containing composition comprising specified amounts of the meso-isomer of one or more of the oxolanyl compounds of specified structure is provided. Also provided are methods for the use of such compositions as vinyl content modifiers in polymerization processes. 125-. (canceled)26. A vinyl content modifier composition comprising 2 ,2-di(2-tetrahydrofuryl)propane , wherein at least 60% by weight of the 2 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.27. The vinyl content modifier composition of claim 26 , wherein at least 65% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.28. The vinyl content modifier composition of claim 26 , wherein at least 75% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.29. The vinyl content modifier composition of claim 26 , wherein at least 99% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.30. The vinyl content modifier composition of claim 26 , wherein 65-99% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.31. The vinyl content modifier composition of claim 26 , wherein 65-87% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.32. The vinyl content modifier composition of claim 26 , wherein at least about 65 to about 75% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.33. The vinyl content modifier composition of claim 26 , wherein about 65 to about 87% by weight of the 2 claim 26 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.35. The vinyl content modifier composition of claim 34 , wherein at least 65% by weight of the 2 claim 34 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.36. The vinyl content modifier composition of claim 34 , wherein at least 75% by weight of the 2 claim 34 ,2-di(2-tetrahydrofuryl)propane is meso-isomer.37. The vinyl content modifier composition of claim 34 , wherein at least 99% by weight of the 2 claim 34 ,2-di(2-tetrahydrofuryl) ...

Подробнее
26-05-2016 дата публикации

METHODS FOR PREPARATION OF LYCOPENES FROM C15-WITTIG SALTS AND METHODS FOR PURIFICATION OF HIGH ALL-E CONTAINING AND HIGH 6Z CONTAINING C15-WITTIG SALTS

Номер: US20160145173A1
Автор: CHIU Haw-Shyi, Lin Po-Wei
Принадлежит:

The present invention relates to methods for preparation of lycopenes, especially to lycopenes with high all-E contents or high 6Z contents from C15-Wittig slats mixtures. (with high all-E-contents and high 6Z-contents, respectively). C15-Wittig slats mixtures are purified and 6Z-C15-Wittig salts are extracted from the mixtures. The extracted 6Z-C15-Wittig salts are, used in the synthesis of lycopenes with high 6Z contents and the residues are used in the synthesis of lycopenes with high All-E contents. 121-. (canceled)22. A method for synthesis of lycopenes which comprisesobtaining a C15-Wittig salt cis/trans mixture;purifying the C15-Wittig salt cis/trans mixture to remove solvents;adding an aprotic solvent comprising acetone to the C15 Wittig salt cis/trans mixture to extract 6Z-C15-Wittig salts from the mixture;removing the 6Z-C15-Wittig salts from the mixture to obtain residues;purifying the obtained residues to obtain C15-Wittig salts with high all-E contents; andreacting said obtained C15-Wittig salts with a C10-dialdehyde in a double-Wittig reaction in the present of a base reactant to obtain said lycopenes.23. The method according to claim 22 , wherein purifying the C15 Wittig salt cis/trans mixture includes adding the aprotic solvent to the C15 Wittig salt cis/trans mixture and stirring the composition at 30° C. for over 10 hours.24. The method according to claim 23 , wherein the aprotic solvent includes ethyl acetate.25. The method according to claim 23 , wherein the composition is stirred for 16 hours.26. The method according to claim 22 , wherein purifying the residue includes adding the aprotic solvent to the C15 Wittig salt cis/trans mixture and stirring the composition at 25° C. to −30° C. for over 10 hours.27. The method according to claim 26 , wherein the aprotic solvent includes ethyl acetate.28. A method for synthesis of lycopenes claim 26 , comprising:obtaining a C15-Wittig salt cis/trans mixture;purifying the C15-Wittig salt cis/trans mixture ...

Подробнее
02-06-2016 дата публикации

NEW PROCESS FOR THE MAINTAINING OF A RATIO OF ISOMERS OF CAROTENOID COMPOUNDS

Номер: US20160152540A1
Принадлежит:

The present invention relates to process for the maintaining of a ratio stereoisomers of carotenoid compounds by using at least one alkali and/or earth alkali metal salt of an organic acid, to specific formulations and to the use of such specific formulations. 5. Process according to wherein the alkali and/or earth alkali metal salts of an organic acid are compounds of formulae{'sup': '1', 'sub': 2', '2, 'R—COOMeor (R—COO)Me,'}{'sub': '1', 'wherein R is a C-C4-alkyl group, and'}{'sup': '1', 'Meis an alkali cation, and'}{'sup': '2', 'Meis an earth alkali cation.'}6. Process according to claim 1 , wherein the alkali and/or earth alkali metal cations are K claim 1 , Ca+and/or Mg+ salts.7. Process according to claim 1 , wherein CHCOOK used.8. Process according to wherein 0.0001 wt-% to 1 wt. % claim 1 , based on the total weight of the compound(s) of formula (I) claim 1 , of the alkali and/or earth alkali metal salt of an organic acid is used.13. Formulation according to wherein the alkali and/or earth alkali metal salts are salts from an organic acid of formulae{'sup': '1', 'sub': 2', '2, 'R—COOMeor (R—COO)Me,'}{'sub': '1', 'wherein R is a C-C4-alkyl group, and'}{'sup': '1', 'Meis an alkali cation, and'}{'sup': '2', 'Meis an earth alkali cation.'}14. Formulation according to claim 9 , wherein the alkali and/or earth alkali metal cations of the alkali and/or earth alkali metal of the organic acids are K claim 9 , Ca+ and/or Mg.15. Formulation according to claim 9 , wherein CHCOOK is the salt.16. Formulation according to wherein 0.0001 wt-% to 1 wt-% claim 1 , based on the total weight of the compound(s) of formula (I) claim 1 , of the alkali and/or earth alkali metal salt of an organic acid is comprised.17. Use of at least one formulation according to in food claim 9 , feed or personal care products.18. Food claim 9 , feed or personal care product comprising at least one formulation of . The present invention relates to a process for the maintaining of a ratio of ...

Подробнее
02-06-2016 дата публикации

PROCESS FOR THE PREPARATION OF CLOMIPHENE

Номер: US20160152551A1
Принадлежит:

An improved process for the preparation of the active pharmaceutical ingredient Clomiphene and, in particular, trans-Clomiphene, using acetic acid or trifluoroacetic acid is disclosed. 2. The process according to the claim 1 , wherein the amount of acetic acid or trifluoroacetic acid is between 1 and 3 volumes.3. The process according to claim 1 , wherein the organic solvent is methylene chloride.4. The process according to claim 2 , wherein the amount of methylene chloride is between 5 and 11 volumes.5. The process according to claim 1 , wherein the amount of acetic acid or trifluoroacetic acid is between 1 and 3 volumes and the amount of methylene chloride is between 5 and 11 volumes.6. The process according to the claim 5 , wherein the amount of acetic acid or trifluoroacetic acid is about 2 volumes and the amount of methylene chloride is about 8 volumes.7. The process according to claim 1 , wherein the reacting is performed at a temperature between 20° C. and 40° C.8. The process according to claim 1 , wherein the amount of chlorinating agent is in the range of from 0.45 to 0.60 molecular equivalents.9. The process according to claim 1 , wherein the chlorinating agent is dichlorodimethylhydantoin.10. The process according to claim 1 , wherein the reacting is carried out under anhydrous conditions.12. The process according to claim 11 , wherein the reacting step and the adding of racemic binaphthyl-phosphoric acid are carried out one pot.14. The process according to claim 1 , wherein the Clomiphene prepared by said process is a mixture of trans-Clomiphene and cis-Clomiphene in ratio from 75:25 to 99:1. This application claims the benefit of priority from European Patent Application No. EP 14190736.0, filed Oct. 28, 2014, the disclosure of which is incorporated herein.The present invention refers to a process for the preparation the active pharmaceutical ingredient named Clomiphene and, in particular, trans-Clomiphene.Clomiphene is an active pharmaceutical ...

Подробнее
16-05-2019 дата публикации

NEW ADIPATE-TYPE COMPOUNDS AND A PROCESS OF PREPARING IT

Номер: US20190144415A1
Принадлежит: Haldor Topsoe A/S

The present invention regards new adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and copolymers. The invention also regards the process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.

Подробнее
16-05-2019 дата публикации

ETHYNYL DERIVATIVES

Номер: US20190144458A1
Принадлежит: Hoffmann-La Roche Inc.

The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.

Подробнее
09-06-2016 дата публикации

Metal-organic frameworks for aromatic hydrocarbon separations

Номер: US20160159713A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides for metal organic frameworks (MOFs) that are selective adsorbents for aromatic hydrocarbons, devices comprising the MOFs thereof, and methods using the MOFS thereof for separating and/or storing aromatic hydrocarbons.

Подробнее
07-06-2018 дата публикации

MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF

Номер: US20180155289A1
Автор: Zhang Haoming
Принадлежит:

This invention is in the field of medicinal chemistry. In particular, the invention relates to mixed disulfide conjugates of thienopyridine compounds, and their use as therapeutics for the treatment, amelioration, and prevention of cardiovascular diseases. 2. (canceled)3. (canceled)4. (canceled)5. The compound of claim 1 , wherein the compound has one or more of the following stereochemical configurations: a) the double bond connected with the R4 substituent is either in a Z or cis configuration; b) the C7 carbon is either in a racemic claim 1 , R or S configuration; and c) the C4 carbon is either in a racemic claim 1 , R or S configuration.7. (canceled)8. The compound of claim 1 , wherein the R4 substituent is engaged with an applicable metal to form a salt claim 1 , wherein the applicable metal is selected from Na claim 1 , K claim 1 , and Li claim 1 , orwherein the R4 substituent is engaged with an applicable halogen to form an ammonium salt.9. (canceled)12. (canceled)13. (canceled)14. The compound of claim 1 , wherein R3 is selected from the group consisting of Cl claim 1 , Br claim 1 , I claim 1 , F claim 1 , CN claim 1 , NO claim 1 , CF claim 1 , H claim 1 , and OCH.16. (canceled)17. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.18. (canceled)19. A method of treating claim 1 , ameliorating claim 1 , or preventing a cardiovascular disease in a patient comprising administering to said patient a therapeutically effective amount of the compound of claim 1 , wherein said administration is selected from the group consisting of oral administration and intravenous administration claim 1 , wherein said cardiovascular disease is selected from the group consisting of coronary artery disease claim 1 , peripheral vascular disease claim 1 , atherothrombosis claim 1 , and cerebrovascular disease.20. (canceled)21. (canceled)22. The method of claim 19 ,{'sub': '12', 'wherein said compound reduces aggregation of platelets, ...

Подробнее
24-06-2021 дата публикации

PROCESS FOR CATALYTIC CONVERSION OF MIXTURES OF HCFO-1233zd(Z) AND HCFC-244fa INTO HCFO-1233zd(E)

Номер: US20210188744A1
Принадлежит:

A method for conversion of a composition containing HCFO-1233zd(Z) and HCFC-244fa to form HCFO-1233zd(E) by reacting a mixture including HCFO-1233zd(Z) and HCFC-244fa in a vapor phase in the presence of a catalyst to simultaneously isomerize HCFO-1233zd(Z) to form HCFO-1233zd(E) and dehydrohalogenate HCFC-244fa to form HCFO-1233zd(E). The catalyst may be a chromium-based catalyst such as chromium trifluoride, chromium oxyfluoride, or chromium oxide, for example. 1. A method for simultaneous conversion of a mixture of HCFO-1233zd(Z) and HCFC-244fa to form HCFO-1233zd(E) , comprising the steps of:providing a mixture including HCFO-1233zd(Z) and HCFC-244fa; andreacting the HCFO-1233zd(Z) and HCFC-244fa mixture in a vapor phase in the presence of a catalyst to simultaneously isomerize HCFO-1233zd(Z) to form HCFO-1233zd(E) and dehydrohalogenate HCFC-244fa to form HCFO-1233zd(E).2. The method of claim 1 , wherein the catalyst is a chromium-based catalyst.3. The method of claim 1 , wherein the catalyst comprises a catalyst selected from the group consisting of chromium trifluoride (CrF) claim 1 , chromium oxide (CrO) claim 1 , and chromium oxyfluoride (CrOF claim 1 , where x may be 1 or 2 claim 1 , y may be 1 or 2 claim 1 , and z may be 1 claim 1 , 2 claim 1 , or 4) claim 1 , and combinations thereof.410.-. (canceled)11. The method of claim 1 , wherein said reacting step is conducted at a temperature between 80° C. and 170° C.12. The method of claim 11 , wherein said reacting step is conducted at a temperature between 100° C. and 275° C.13. The method of claim 1 , wherein a contact time between the composition and the catalyst is between 1 second and 150 seconds.14. The method of claim 1 , wherein a pressure in the reactor is between 0 psig and 100 psig.15. The method of claim 1 , wherein during the reacting step claim 1 , the reactor includes less than 50 ppm water.16. The method of claim 1 , wherein in the providing step claim 1 , total impurities are present in an ...

Подробнее
24-06-2021 дата публикации

SYNTHESIS OF ALIPHATIC ALCOHOLS AS AROMA CHEMICALS

Номер: US20210188748A1
Принадлежит:

The present invention relates to a method for preparing a compound of formula (I). The present invention also relates to compounds of formula (A) or a compound in the form of a stereoisomer. The present invention further relates to the use of a compound of formula (A) as aroma chemical. 3. The process according to the claim 1 , wherein steps (b) claim 1 , (c) and (d) and/or steps (b) and (c) and/or steps (c) and (d) are carried out in a single pot.4. The process according to the claim 1 , wherein the peroxyacid in step b) is selected from the group consisting of peroxymonosulfuric acid claim 1 , peroxyphosphoric acid claim 1 , peroxyacetic acid claim 1 , peroxyformic acid claim 1 , peroxytrifluoroacetic acid claim 1 , potassium peroxymonosulfate claim 1 , sodium perborate claim 1 , peroxynitric acid and peroxybenzoic acid.5. The process according to the claim 4 , wherein the peroxybenzoic acid is meta-chloroperoxybenzoic acid.6. The process according to the claim 1 , wherein the peroxide in step b) is selected from the group consisting of hydrogen peroxide.7. The process according to claim 1 , wherein step d) is carried out in the presence of an acid.8. The process according to claim 7 , wherein the acid is selected from the group consisting of methanesulfonic acid claim 7 , phosphoric acid claim 7 , p-toluenesulfonic acid claim 7 , formic acid claim 7 , sulfuric acid claim 7 , hydrochloric acid and acetic acid.10. The compound of claim 9 , wherein Ris H or methyl;{'sup': 2', '5, 'Ris selected from the group consisting of H, methyl, ethyl, 1-propyl, 1-methylethyl, and cyclopropyl; Ris selected from the group consisting of methyl, ethyl, 1-propyl, 1-methylethyl, and cyclopropyl;'}{'sup': '4', 'Ris selected from the group consisting of H, ethyl, 1-propyl, 1-methylethyl, and cyclopropyl;'}{'sup': '3', 'and Ris H.'}12. A composition comprising at least one compound selected from the the mixture of compounds of the formulae (A.a) claim 9 , (A.b) and (A.c) according to . ...

Подробнее
16-06-2016 дата публикации

FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF ACIDS

Номер: US20160168110A1
Принадлежит:

The present invention relates to a synthesis of chromanones or chromanes in a stereospecific matter in view of the 2-position in the chromanone or chromane ring. It has been found that this synthesis is particularly possible in the presence of a chiral compound of a specific type and of at least one Bransted acid or in the presence a specific chiral compound having a Bransted acid functional group in the molecule. 5. Process according to wherein the Brønsted acid is selected from the group consisting of trifluormethane sulphonamide claim 1 , p-nitrobenzoic acid claim 1 , 3 claim 1 ,5-dinitrobenzoic acid and 3 claim 1 ,5-bis(trifluoromethyl)benzoic acid.6. Process according to wherein the ratio of molar amounts of Brønsted acid to chiral compound of formula (II-C) is between 1:2 and 4:1 claim 1 , preferably in the range from 1:1 and 2:1.9. Process according to claim 1 , wherein the isomer having the R-configuration at the chiral centre marked by * in formula (I) or (V) is preferentially formed in respect to the corresponding isomer having the S-configuration at said chiral centre.13. Composition according to anyone of the preceding to wherein the Brønsted acid is selected from the group consisting of trifluormethane sulphonamide claim 1 , p-nitrobenzoic acid claim 1 , 3 claim 1 ,5-dinitrobenzoic acid and 3 claim 1 ,5-bis(trifluoromethyl)benzoic acid.14. Composition according to wherein the ratio of molar amounts of Brønsted acid to chiral compound of formula (II-C) is between 1:2 and 4:1 claim 10 , preferably in the range from 1:1 and 2:1.15. 6-hydroxy-2 claim 10 ,7 claim 10 ,8-tri-methyl-2-(4 claim 10 ,8 claim 10 ,12-trimethyltridecyl)chroman-4-one. The present invention relates to the field of the synthesis of tocopherols and tocotrienols.Chromane compounds represent an important class of chiral natural products and bioactive compounds. An important class of chromane compounds are vitamin E and its esters. Often vitamin E is commercialized in the form of its esters ...

Подробнее
16-06-2016 дата публикации

FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS

Номер: US20160168111A1
Принадлежит:

The present invention relates to a synthesis of chromanones or chromanes in a stereospecific matter in view of the 2-position in the chromanone or chromane ring. It has been found that this synthesis is particularly possible in the presence of a chiral compound of formula of a specific type and of at least one phenol or thiophenol. 3. Process according to wherein{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R′R═R═CH'}{'br': None, 'or'}{'br': None, 'sup': 1', '4', '3, 'sub': '3', 'R═R═CH, R═H'}{'br': None, 'or'}{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R═H, R═R═CH.'}{'br': None, 'or'}{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R═R═H, R═CH.'}5. Process according to wherein the organic catalyst having at least one phenolic group or thiophenolic group is a selected from the group consisting of phenol claim 1 , 4-nitrophenol claim 1 , 2 claim 1 ,4-dinitrophenol claim 1 , 1-naphthol claim 1 , 2-naphthol and 8-hydroxyquinoline.6. Process according to wherein the organic catalyst having at least one phenolic group or thiophenolic group is a selected from the group consisting of thiophenol claim 1 , p-nitrothiophenol claim 1 , 2 claim 1 ,4-dinitrothiophenol claim 1 , 1-naphthalenethiol claim 1 , 2-naphthalenethiol and 4-trifluormethyl-tetrafluorthiophenol.8. Process according to claim 1 , wherein the isomer having the R-configuration at the chiral centre marked by * in formula (I) or (V) is preferentially formed in respect to the corresponding isomer having the S-configuration at said chiral centre.11. Composition according to wherein{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R═R═R═CH'}{'br': None, 'or'}{'br': None, 'sup': 1', '4', '3, 'sub': '3', 'R═R═CH, R═H'}{'br': None, 'or'}{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R═H, R═R═CH'}{'br': None, 'or'}{'br': None, 'sup': 1', '3', '4, 'sub': '3', 'R═R═H, R═CH.'}13. Composition according to wherein the organic catalyst having at least one phenolic group or thiophenolic group is a selected from the group consisting ...

Подробнее
06-06-2019 дата публикации

Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Номер: US20190167626A1
Принадлежит: UNIVERSITY OF WASHINGTON

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

Подробнее
06-06-2019 дата публикации

PIPERDINE CXCR7 RECEPTOR MODULATORS

Номер: US20190169180A1
Принадлежит:

The present invention relates to piperidine derivatives of formula (I) 3. The compound according to ; wherein Rrepresents hydrogen;or a pharmaceutically acceptable salt thereof.4. The compound according to ; wherein Arrepresents oxazol-2 claim 3 ,5-diyl claim 3 , oxazol-2 claim 3 ,4-diyl claim 3 , isoxazol-3 claim 3 ,5-diyl claim 3 , [1 claim 3 ,3 claim 3 ,4]oxadiazol-2 claim 3 ,5-diyl claim 3 , [1 claim 3 ,2 claim 3 ,4]oxadiazol-3 claim 3 ,5-diyl claim 3 , or 1H-[1 claim 3 ,2 claim 3 ,3]triazol-1 claim 3 ,4-diyl; wherein said 5-membered heteroarylene is unsubstituted;or a pharmaceutically acceptable salt thereof.5. The compound according to ; wherein Arrepresents phenyl which is mono- claim 4 , di- or tri-substituted; wherein one or two of said substituents is/are independently selected from fluoro claim 4 , chloro claim 4 , or methyl claim 4 , and the remaining claim 4 , if present claim 4 , is/are fluoro;or a pharmaceutically acceptable salt thereof.7. The compound according to ; wherein{'sup': 1', 'N1', 'N2, 'claim-text': {'sup': 'N1', 'claim-text': [{'sub': 3-6', '3-6', '3-6, '(C)cycloalkyl, wherein said (C)cycloalkyl optionally contains one ring oxygen atom; wherein said (C)cycloalkyl independently is unsubstituted, or mono-substituted with fluoro, methyl, or hydroxy, or di-substituted with fluoro, or tri-substituted with methyl and two fluoro;'}, {'sub': 3-6', '1-3', '3-6, '(C)cycloalkyl-(C)alkylene-, wherein said (C)cycloalkyl optionally contains one ring oxygen atom;'}, {'sub': 3-6', '3-5, '(C)cycloalkyl-(C)cycloalkylene-;'}, {'sub': 1-4', '1-4', '1-4', '1-3', '1-3, 'phenyl-(C)alkylene- wherein said phenyl is unsubstituted, or mono-, or di-substituted; wherein the substituents are independently selected from (C)alkyl, (C)alkoxy, halogen, (C)fluoroalkyl, or (C)fluoroalkoxy;'}, {'sub': 1-3', '1-3, 'phenyl-(C)alkylene- wherein said —(C)alkylene- is mono-substituted with hydroxy;'}, {'sub': 3-5', '3-5', '1-4', '1-4', '1-3', '1-3, 'phenyl-(C)cycloalkylene-; ...

Подробнее
30-06-2016 дата публикации

PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS

Номер: US20160185683A1
Принадлежит:

The present invention relates to a process of the asymmetric hydrogenation of a ketal of an unsaturated ketone or an acetal of an unsaturated aldehyde by molecular hydrogen in the presence of at least one chiral iridium complex. This process yields chiral compounds in a very efficient way and is very advantageous in that the amount of iridium complex can be remarkably reduced. 1. A process of the asymmetric hydrogenation of a ketal of an unsaturated ketone or an acetal of an unsaturated aldehyde by molecular hydrogen in the presence of at least one chiral iridium complex to yield a ketal or acetal having at least one stereogenic carbon centre.2. The process according to wherein the ketal or acetal is obtained from the reaction of the corresponding unsaturated ketone or the corresponding unsaturated aldehyde and an alcohol claim 1 , particularly a monol or a diol claim 1 , preferably an alcohol which is halogenated C-C-alkyl alcohol or which is selected from the group consisting of ethane-1 claim 1 ,2-diol claim 1 , propane-1 claim 1 ,2-diol claim 1 , propane-1 claim 1 ,3-diol claim 1 , butane-1 claim 1 ,4-diol claim 1 , butane-1 claim 1 ,3-diol claim 1 , butane-1 claim 1 ,2-diol claim 1 , butane-2 claim 1 ,3-diol claim 1 , 2-methylpropane-1 claim 1 ,2-diol claim 1 , 2-methylpropane-1 claim 1 ,3-diol claim 1 , 2 claim 1 ,2-dimethylpropane-1 claim 1 ,3-diol claim 1 , 1 claim 1 ,2-dimethylpropane-1 claim 1 ,3-diol claim 1 , 3-methylpentane-2 claim 1 ,4-diol and 2-(hydroxymethyl)cyclohexanol claim 1 , benzene-1 claim 1 ,2-diol and cyclohexane-1 claim 1 ,2-diols.3. The process according to wherein the unsaturated ketone or unsaturated aldehyde is a ketone or an aldehyde having a carbon-carbon double bond in the α claim 1 ,β-position to the C═O group.4. The process according to wherein the unsaturated ketone or unsaturated aldehyde is a ketone or an aldehyde having a carbon-carbon double bond in the γ claim 1 ,δ-position to the C═O group.6. The process according to ...

Подробнее
30-06-2016 дата публикации

SELECTIVE OLEFIN METATHESIS WITH CYCLOMETALATED RUTHENIUM COMPLEXES

Номер: US20160185684A1
Принадлежит:

This invention relates generally to C—H activated ruthenium olefin metathesis catalyst compounds which are stereogenic at the ruthenium center, to their preparation, and the use of such catalysts in the metathesis of olefins and olefin compounds. In particular, the invention relates to the use of C—H activated ruthenium olefin metathesis catalyst compounds in Z-selective olefin metathesis reactions, enantio-selective olefin metathesis reactions, and enantio-Z-selective olefin metathesis reactions. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry. 2. The olefin metathesis catalyst complex claim 1 , according to claim 1 , wherein:{'sup': '1', 'sub': 1', '6', '1', '6, 'Ris C-Calkyl, C-Calkoxy, or halide;'}{'sup': '2', 'sub': 2', '6', '1', '6', '2', '2', '3', '5', '8', '5', '8', '1', '6', '1', '6, 'Ris C-Calkyl, substituted C-Calkyl, (e.g., CFH, CFH, CF, etc.), C-Ccycloalkyl, C-Csubstituted cycloalkyl, heteroatom-containing hydrocarbyl, or substituted heteroatom-containing hydrocarbyl, where the substituents are selected from C-Calkyl, C-Calkoxy, or halide;'}{'sup': 4', '5', '6', '7', '8, 'R, R, R, Rand Rare independently hydrogen;'}Y is O;{'sub': 1', '6, 'Z is C-Calkyl;'}n is 1; and{'sup': 1', '−, 'sub': 3', '2, 'Xis NO or t-BuCO.'}3. The olefin metathesis catalyst complex claim 2 , according to claim 2 , wherein:{'sup': '1', 'Ris Me, OMe or F;'}{'sup': '2', 'sub': '3', 'Ris MeO, iPr, Me, F, or CF; and'}Z is i-Pr.4. The olefin metathesis catalyst complex claim 2 , according to claim 2 , wherein:{'sup': '1', 'Ris Me, OMe, or F;'}{'sup': '2', 'sub': '3', 'Ris MeO, Me, iPr, or CF;'}Z is i-Pr; and{'sup': 1', '−, 'sub': '3', 'Xis NO.'}5. The olefin metathesis catalyst complex claim 2 , according to claim 2 , wherein:{'sup': '1', 'Ris MeO, Me or F;'}{'sup': '2', 'sub': '3', 'Ris MeO, iPr, Me or CF;'}Z is i-Pr; and{'sup': '1', 'sub': '2', 'Xis t-BuCO.'}7. A method for performing an enantio- ...

Подробнее
28-06-2018 дата публикации

12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME

Номер: US20180179174A1
Принадлежит: Thesan Pharmaceuticals Inc

The present invention provides compounds of the following structure, methods of using such compounds, and pharmaceutical compositions containing such compounds. In addition, this invention provides methods for the treatment and/or prevention of disease states mediated by Aryl Hydrocarbon receptor pathways.

Подробнее
13-06-2019 дата публикации

HIGH TEMPERATURE ISOMERIZATION OF (E)-1-CHLORO-3,3,3-TRIFLUOROPROPENE TO (Z)-1-CHLORO-3,3,3-TRIFLUOROPROPENE

Номер: US20190177252A1
Принадлежит:

Disclosed are processes for a high temperature isomerization reaction converting (E)-1-chloro-3,3,3-trifluoropropene to (Z)-1-chloro-3,3,3-trifluoropropene. In certain aspects of the invention, such a process includes contacting a feed stream with a heated surface, where the feed stream includes (E)-1-chloro-3,3,3-trifluoropropene or mixture of (E)-1-chloro-3,3,3-trifluoropropene with (Z)-1-chloro-3,3,3-trifluoropropene. The resulting product stream includes (Z)-1-chloro-3,3,3-trifluoropropene and (E)-1-chloro-3,3,3-trifluoropropene, where the ratio of (Z) isomer to (E) isomer in the product stream is higher than the ratio feed stream. The (E) and (Z) isomers in the product stream may be separated from one another. 1. A method of converting (E)1-chloro-3 ,3 ,3-trifluoropropene into (Z)1-chloro-3 ,3 ,3-trifluoropropene , comprising:providing a reaction mixture comprising (E)1-chloro-3,3,3-trifluoropropene and, optionally, (Z)-1-chloro-3,3,3-trifluoropropene;heating said reaction mixture to temperature of greater than 400° C. for a period of time and under conditions effective to form a product mixture comprising a concentration of (Z)1-chloro-3,3,3-trifluoropropene that is greater than that provided in the reaction mixture.2. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 550° C.3. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 500° C.4. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 475° C.5. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 450° C.6. The method of claim 1 , further comprising the step of providing a temperature controlled reaction vessel that includes an interior surface claim 1 , a first opening claim 1 , a second opening claim 1 , a pathway fluidly connecting the first and ...

Подробнее
29-06-2017 дата публикации

Novel ep4 agonists as therapeutic compounds

Номер: US20170183293A1
Принадлежит: Allergan Inc

Described herein are compounds that are EP 4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP 4 receptors.

Подробнее
18-09-2014 дата публикации

Methods for removing halogenated ethylene impurities in 2,3,3,3-tetrafluoropropene product

Номер: US20140275655A1
Принадлежит: Honeywell International Inc

The present process relates to a process comprising: contacting a mixture comprising 2,3,3,3-tetrafluoropropene and at least one halogenated ethylene impurity with at least one adsorbent or at least one chemisorption catalyst to reduce the concentration of said at least one halogenated ethylene impurity.

Подробнее
20-06-2019 дата публикации

GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

Номер: US20190185502A1
Принадлежит:

There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis. 2. The compound of claim 1 , wherein one or more of R claim 1 , R claim 1 , R claim 1 , and Ris independently in the form of QC(═O)— claim 1 , where Qis selected from unsubstituted or substituted alkyl claim 1 , alkenyl claim 1 , alkynyl claim 1 , aryl claim 1 , heteroaryl claim 1 , carbocyclic claim 1 , heterocyclic group with or without a substituent group claim 1 , alkoxy claim 1 , aryloxy claim 1 , arylalkyloxy claim 1 , and alkylaryloxy; and an amino or hydroxyl group in Q claim 1 , if present claim 1 , is optionally substituted.7. The compound of claim 1 , wherein the compound is an alpha-anomer claim 1 , a beta-anomer claim 1 , or a mixture of alpha- and beta-anomers.9. The compound of claim 1 , wherein the C claim 1 , H claim 1 , O claim 1 , and/or N atoms in the compound are each independently selected from atoms of natural abundance and isotope-enriched atoms.10. The compound of claim 9 , wherein the C atoms in the compound are independently selected from C claim 9 , C claim 9 , and C; the H atoms in the compound are independently selected from H claim 9 , H claim 9 , and H; the O-atoms in the compound are independently selected from O claim 9 , O claim 9 , and O; and the N atoms in the compound are independently selected from N and N.11. A pharmaceutical composition comprising the compound of and a pharmaceutically acceptable carrier.12. The pharmaceutical composition of claim 11 , wherein the composition is suitable for oral or topical administration.13. The pharmaceutical composition of claim 11 , wherein the composition is in the form of a hard shell gelatin capsule claim 11 , a soft shell gelatin capsule claim 11 , a cachet claim 11 , a pill claim 11 , a tablet claim 11 , a lozenge claim 11 , a ...

Подробнее
14-07-2016 дата публикации

NEW SALVIANOLIC ACID COMPOUND T, PREPARATION METHOD THEREFOR, AND USE THEREOF

Номер: US20160200661A1
Принадлежит:

The present invention relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound. 2. A preparation method of the salvianolic acid T according to claim 1 , wherein claim 1 , the method includes the following steps:(1a) extraction:extracting Radix Salviae Miltiorrhizae crude drug or a mixture of Radix Salviae Miltiorrhizae and other crude drugs with water, concentrating the filtrate to obtain a water extract, then adding alcohol to precipitate and obtain a supernatant, concentrating the supernatant to obtain an alcohol extract;(1b) separation: diluting the alcohol extract of the step (1a) in water, applying on the macroporous absorbent resin, washing the resin with an acidic aqueous solution to remove impurities and then eluting the resin with ethanol to obtain an ethanol eluent, concentrating the ethanol eluent to obtain an extract;Or, replacing the above steps (1a) and (1b) by the following step (1):(1)Synthesis:dissolving salvianolic acid B in the water, heating;(2) purification: adjusting the pH of the reaction liquid obtained in the step (1) to be acidic or purifying the extract obtained in the step (1b) by the preparative high pressure liquid chromatograph, with C18 reversed phase silica gel column as the chromatographic packing, acetonitrile-water-formic acid as the eluent, carrying out isocratic elution or gradient elution, with a detection wavelength of 280 nm; monitoring the elution process by high performance liquid chromatography, collecting the eluent containing salvianolic acid T; concentrating to obtain the salvianolic acid T.3. A preparation method of the chiral isomers of salvianolic acid T according to claim 1 , wherein claim 1 , the method includes the following steps:(1a) extraction: extracting Radix Salviae Miltiorrhizae crude drug or a mixture ...

Подробнее
27-06-2019 дата публикации

IMPROVED METHOD FOR THE SYNTHESIS OF PERMETHRIN

Номер: US20190194118A1
Принадлежит:

The present invention describes an improved method for the synthesis of substantially pure Permethrin (1) having purity greater than 99.5% by Gas Chromatography (GC). The invention also relates to a purification process of Permethrin by recrystallization from methanol-water mixture. 2. The process of claim 1 , wherein Permethrin obtained is devoid of major reaction impurities Imp A claim 1 , B claim 1 , C claim 1 , D claim 1 , E claim 1 , F claim 1 , G and H and total impurities are less than 0.5%.3. A process for preparation of substantially pure Permethrin with greater than 99.5% purity comprising the steps of:I. Coupling of 3-phenoxybenzyl alcohol with 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarbonyl chloride, in a suitable solvent to yield PermethrinII. Purifying the Permethrin obtained in step I by recrystallizing in methanol and water mixture to obtain a substantially pure PermethrinIII. Blending pure Permethrin of step II with pure trans to obtain substantially pure Permethrin with desired isomeric ratio.4. The process of claim 3 , wherein Permethrin obtained is devoid of major reaction impurities Imp A claim 3 , B claim 3 , C claim 3 , D claim 3 , E claim 3 , F claim 3 , G and H and total impurities are less than 0.5%.5. The process of claim 3 , wherein the coupling reaction of step I is carried out in the presence of organic solvent selected from the group comprising of toluene claim 3 , dichloromethane claim 3 , ethyl acetate claim 3 , methyl tertiary butyl ether or mixtures thereof.6. The process of claim 3 , wherein the coupling reaction of step I is carried out at temperature 80°-85° C.7. A process for the purification of Permethrin comprising recrystallizing it from a mixture of methanol and water. This application claims priority from Indian patent application no. 201641030143 dated Sep. 2, 2016 filed in Indian Patent Office.The present invention describes an improved method for the synthesis of substantially pure pharmaceutical grade Permethrin ...

Подробнее
04-07-2019 дата публикации

COMPOSITION CONTAINING STILBENE GLYCOSIDE AND PREPARATION AND USES THEREOF FOR TREATING DIABETES

Номер: US20190201428A1
Принадлежит:

Disclosed is a method of processing the method contains preparing a root extract solution and placing the solution under UV light for 1 to 24 hours. Also disclosed is a composition prepared from the method that can be for use in the prevention, treatment, and management of diabetes in human and animal subjects. 1Polygonum multiflorum. A method of processing (PM) , the method comprising:crushing dried roots of PM to powder;extracting the PM powder with an ethanol solution under the room temperature for at least 2 days to obtain an ethanolic extract, the ratio of solution to solid being about 1:10 (v/w);evaporating and concentrating the ethanolic extract under reduced pressure to obtain a dried extract; andsubjecting the dried extract to macroporous resin chromatography, followed by eluting the resin with ethanol solutions of different concentrations to obtain a first eluant;evaporating and drying the first eluant under reduced pressure to obtain PM extract powder;dissolving the obtained PM extract powder in an aqueous solution to obtain a PM solution; andplacing the PM solution under UV light for 1 to 24 hours, whereby an UV-treated PM solution is obtained.2. The method of claim 1 , wherein the PM solution comprises trans-2 claim 1 ,3 claim 1 ,5 claim 1 ,4-tetrahydroxystilbene 2-O-β-glucopyranoside (stilbene glycoside) at a concentration of 1-50 mg/ml.3. The method of claim 1 , wherein the PM solution comprises trans-2 claim 1 ,3 claim 1 ,5 claim 1 ,4-tetrahydroxystilbene 2-O-β-glucopyranoside (stilbene glycoside) at a concentration of 2-20 mg/ml.4. The method of claim 2 , wherein the UV light has a wavelength of approximately 365 nm.5. The method of claim 4 , wherein the PM solution is placed under the UV light for 5-15 hrs.6. The method of claim 1 , wherein the UV-treated PM solution comprises cis-stilbene glycoside and trans-stilbene glycoside claim 1 , the ratio of cis-stilbene glycoside to trans-stilbene glycoside being greater than 1:1.7. The method of claim 6 ...

Подробнее
26-07-2018 дата публикации

METHOD FOR PRODUCING A CYCLIC ISOCYANATE

Номер: US20180208550A1
Принадлежит: BASF SE

The present invention relates to a process for preparing a cyclic isocyanate (B) from a composition (Z) which comprises at least one component (A) which has at least one cycloalkane ring having at least 4 ring carbons, where the cycloalkane ring has two NHgroups in β or γ positions relative to one another as substituents and in more than 50 mol % of the total amount of component (A) the two NHgroups in β or in γ positions relative to one another assume a trans configuration relative to one another. This composition (Z) is, in the process of the invention, reacted with phosgene to give a composition (ZP) which comprises at least one cyclic isocyanate (B) having isocyanate groups. 1. A process for preparing a cyclic isocyanate (B) , the process comprising reacting a composition (Z) with phosgene to give a composition (ZP) comprising at least one cyclic isocyanate having two isocyanate groups ,wherein:the composition (Z) comprises at least one component (A) comprising at least one cycloalkane ring having at least 4 ring carbons;{'sub': '2', 'the cycloalkane ring has two NHgroups in β or γ positions relative to one another as substituents; and'}{'sub': '2', 'in more than 50 mol % of the total amount of component (A), the two NHgroups in β or γ positions relative to one another assume a trans configuration relative to one another.'}3. The process according to claim 2 , wherein:the composition (Z) comprises at least two components (A1) and (A2);{'sub': 1', '1', '12', '2', '3', '4', '1', '2', '3', '4, 'component (A1) is defined according to formula (III), where Ris C-C-alkyl, and R, R, R, R′, R′, R′, and R′ are each H; and'}{'sub': 2', '1', '12', '1', '3', '4', '1', '2', '3', '4, 'component (A2) is defined according to formula (III) where Ris C-C-alkyl, preferably methyl, and R, R, R, R′, R′, R′ and R′ are each H.'}4. The process according to claim 3 , wherein the composition (Z) comprises:from 5 to 50% by weight of the component (A1), based on the total amount of the ...

Подробнее
26-07-2018 дата публикации

Dna-pk inhibitors

Номер: US20180208579A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Подробнее
13-08-2015 дата публикации

Integrated process and methods of producing (e) 1-chloro-3,3,3-trifluoropropene

Номер: US20150224470A1
Принадлежит: Honeywell International Inc

The present invention relates to methods, process, and integrated systems for economically producing (E)-1-chloro-3,3,3-trifluoropropene via vapor phase and/or liquid processes.

Подробнее
02-08-2018 дата публикации

5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUNDS

Номер: US20180215751A1
Принадлежит: ELI LILLY AND COMPANY

The present invention provides a compound of Formula I: 3. The compound or salt according to wherein the compound is N-[4-fluoro-5-[[(2S claim 2 ,4S)-2-methyl-4-[(5-methyl-1 claim 2 ,2 claim 2 ,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide.4. The compound according to which is N-[4-fluoro-5-[[(2S claim 3 ,4S)-2-methyl-4-[(5-methyl-1 claim 3 ,2 claim 3 ,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide.5. The compound according to wherein the compound is crystalline.6. The compound according to which is characterized by a peak in the X-ray powder diffraction spectrum claim 5 , at diffraction angle 2-theta of 12.1° in combination with one or more peaks selected from the group consisting of 15.3° claim 5 , 21.6° claim 5 , 22.2° claim 5 , 22.7° claim 5 , 23.5° claim 5 , 24.3° claim 5 , and 26.8° claim 5 , with a tolerance for the diffraction angles of 0.2 degrees.7. A method of treating Alzheimer's disease in a patient claim 1 , comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.8. A method of treating the progression of mild cognitive impairment to Alzheimer's disease in a patient claim 1 , comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.9. A method of treating progressive supranuclear palsy in a patient claim 1 , comprising administering to a patient in need of such treatment an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.10. A pharmaceutical composition claim 1 , comprising a compound or a pharmaceutically acceptable salt thereof according to with one or more pharmaceutically acceptable carriers claim 1 , diluents claim 1 , or excipients.11. A process for preparing a pharmaceutical composition claim 1 , comprising admixing a compound or a pharmaceutically acceptable salt ...

Подробнее
12-08-2021 дата публикации

METHOD FOR PRODUCING DIFLUOROETHYLENE

Номер: US20210246090A1
Принадлежит: DAIKIN INDUSTRIES, LTD.

The present invention aims to provide an efficient method for obtaining a desired isomer of HFO-1132 from a composition comprising trans-1,2-difluoroethylene (HFO-1132(E)) and cis-1,2-difluoroethylene (HFO-1132(Z)). 1. A method for producing trans-1 ,2-difluoroethylene (HFO-1132(E)) and/or cis-1 ,2-difluoroethylene (HFO-1132(Z)) , comprising the step of:(1) supplying a composition comprising HFO-1132(E) and/or HFO-1132(Z) to a reactor filled with a catalyst to perform an isomerization reaction between the HFO-1132(E) and the HFO-1132(Z).2. A method for producing cis-1 ,2-difluoroethylene (HFO-1132(Z)) , comprising the step of:(1A) supplying trans-1,2-difluoroethylene (HFO-1132(E)) or a composition comprising HFO-1132(E) and HFO-1132(Z) to a reactor filled with a catalyst to perform an isomerization reaction between the HFO-1132(E) and the HFO-1132(Z).3. A method for producing HFO-1132(E) , comprising the step of:(1B) supplying HFO-1132(Z) or a composition comprising HFO-1132(E) and HFO-1132(Z) to a reactor filled with a catalyst to perform an isomerization reaction between the HFO-1132(E) and the HFO-1132(Z).4. The production method according to any one of to , the reaction product obtained in step (1), (1A), or (1B) comprises HFO-1132(E) and HFO-1132(Z), and', 'the method further comprises steps (2) and (3):, 'wherein'}(2) separating the reaction product obtained in step (1), (1A), or (1B) into a first stream comprising the HFO-1132(E) as a main component, and a second stream comprising the HFO-1132(Z) as a main component; and(3) recycling the first stream or the second stream obtained in step (2) to the reactor, to subject the first stream or the second stream to the isomerization reaction.5. The production method according to any one of to , further comprising the step of:(i) subjecting a halogenated ethane to a dehydrohalogenation reaction or a dehalogenation reaction to obtain a composition comprising HFO-1132(E) and HFO-1132(Z), 'the composition comprising HFO ...

Подробнее
11-08-2016 дата публикации

Method for producing bis (aminomethyl) cyclohexane

Номер: US20160229792A1
Принадлежит: Mitsubishi Gas Chemical Co Inc

A method for producing a bis(aminomethyl)cyclohexane having an isomerization step of isomerizing a cis-isomer of 1,4-bis(aminomethyl)cyclohexane and/or a trans-isomer of 1,3-bis(aminomethyl)cyclohexane at the bottom part of a distillation tower to obtain a trans-isomer of 1,4-bis(aminomethyl)cyclohexane and/or a cis-isomer of 1,3-bis(aminomethyl)cyclohexane; and a distillation step of separating the trans-isomer of 1,4-bis(aminomethyl)cyclohexane and/or the cis-isomer of 1,3-bis(aminomethyl)cyclohexane by distillation, in the top part of the distillation tower, in which the isomerization reaction temperature in the isomerization step is 80 to 140° C., and the isomerization step and the distillation step are simultaneously carried out.

Подробнее
11-08-2016 дата публикации

Method for Producing Asymmetric Conjugated Diyne Compound and Method for Producing Z,Z-Conjugated Diene Compound Using the Same

Номер: US20160229829A1
Принадлежит: Shin Etsu Chemical Co Ltd

Provided are a method for efficiently producing an asymmetric conjugated diyne from an inexpensive and safe alternative compound to hydroxylamine hydrochloride and a method for producing a Z,Z-conjugated diene compound from the asymmetric conjugated diyne compound thus obtained. More specifically, provided is a method for producing an asymmetric conjugated diyne compound comprising a step of subjecting a terminal alkyne compound (1): HC≡C—Z 1 —Y 1 to a coupling reaction with an alkynyl halide (2) Y 2 —Z 2 —C≡C—X by using sodium borohydride in water and an organic solvent in the presence of a copper catalyst and a base to obtain the asymmetric conjugated diyne compound (3): Y 2 —Z 2 —C≡C—C≡C—Z 1 —Y 1 . In addition, provided is a method for producing a Z,Z-conjugated diene compound by reducing the resulting asymmetric conjugated diyne compound, or the like.

Подробнее
09-08-2018 дата публикации

MODULATORS OF ROR-GAMMA

Номер: US20180222860A1
Принадлежит:

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders. 4. The compound of claim 3 , wherein Lis CH claim 3 , CHMe claim 3 , O claim 3 , or C(═O).7. The compound of claim 6 , wherein Ris hydrogen claim 6 , (C-C)alkyl claim 6 , hydroxy(C-C)alkyl claim 6 , —(C-C)alkylNH claim 6 , —(C-C)alkyl-N-di(C-C)alkyl claim 6 , or —(C-C)alkoxy-C(O)—NH; and Ris hydrogen.8. The compound of claim 7 , wherein Ris hydroxy(C-C)alkyl.10. The compound of claim 9 , wherein claim 9 , Ris (C-C)alkyl or cyclopropyl.11. The compound of claim 10 , wherein Cyis aryl or heteroaryl claim 10 , each substituted with 1 to 3 groups independently selected from R.12. The compound of claim 11 , wherein Cyis phenyl or pyridyl claim 11 , each substituted with 1 to 3 groups independently selected from R.13. The compound claim 12 , wherein Cyis phenyl or pyridinyl claim 12 , each substituted with 1 to 3 groups independently selected from R claim 12 , wherein at least one Ris —SO—(C-C)alkyl.14. The compound of claim 13 , wherein Cyis pyridinyl substituted with 1 to 3 groups independently selected from R claim 13 , wherein at least one Ris —SO—(C-C)alkyl.15. The compound of claim 14 , wherein Cyis selected from phenyl claim 14 , pyridinyl claim 14 , cyclohexyl claim 14 , tetrahydropyranyl claim 14 , cyclopropyl claim 14 , and cyclobutyl claim 14 , each optionally substituted with 1 to 3 groups independently selected from R.16. The compound of claim 15 , wherein Cyis selected from phenyl claim 15 , pyridinyl claim 15 , piperidinyl claim 15 , cyclohexyl claim 15 , or tetrahydropyranyl claim 15 , each optionally substituted with 1 to 3 groups independently ...

Подробнее
18-08-2016 дата публикации

Vinyl Modifier Composition And Processes For Utilizing Such Composition

Номер: US20160237181A1
Принадлежит: Bridgestone Corp

An oxolanyl compound-containing composition comprising specified amounts of the meso-isomer of one or more of the oxolanyl compounds of specified structure is provided. Also provided are methods for the use of such compositions as vinyl content modifiers in polymerization processes.

Подробнее
16-08-2018 дата публикации

PROCESS FOR PREPARING BTK INHIBITORS

Номер: US20180230155A1
Принадлежит: Genentech, Inc.

Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided. 2. The method of wherein the volume to weight ratio of the solvent system to compound 170 in the reaction mixture is from about 5:1 to about 20:1 liters per kg claim 1 , or about 10:1 liters per kg claim 1 , and the equivalent ratio of compound 181 to compound 170 is greater than 1:1 claim 1 , and the equivalent ratio of the palladium catalyst to compound 170 is from about 0.005:1 to about 0.02:1 claim 1 , or about 0.01:1.4. The method of wherein:the yield of compound 190 is at least 60%, at least 70%, at least 80% or at least 90%, and the purity of compound 190 is at least 99 area % or at least 99.5 area %; andthe yield of compound 200 is at least 60%, at least 70%, at least 80%, or at least 85%, and the purity of compound 200 is at least 99 area % or at least 99.5 area %.6. The method of wherein the ratio of the solvent volume to compound 160 weight in the reaction mixture is from about 5:1 to about 20:1 liters per kg claim 5 , from about 5:1 to about 15:1 liters per kg claim 5 , or about 10:1 liters per kg claim 5 , and wherein the equivalent ratio of catalyst to compound 160 is from about 0.01:1 to about 0.03:1.7. The method of wherein the catalyst is Pd(OAc) claim 6 , the ligand is DPPF claim 6 , the base is potassium carbonate claim 6 , and the solvent is tetrahydrofuran.9. The method of wherein the polar aprotic solvent is THF; the mole ratio of n-butyl lithium to compound 95 is between 1:1 and 2:1 claim 8 , or from about 1.2:1 to about 1.6:1; the first reaction mixture and the second reaction mixture are formed at a temperature of greater than −35° C.; of the solvent volume to ...

Подробнее
25-08-2016 дата публикации

PROCESS FOR THE TRANS-SELECTIVE HYDROBORATION OF INTERNAL ALKYNES

Номер: US20160244466A1
Принадлежит: STUDIENGESELLSCHAFT KOHLE MBH

The present invention refers to a process for the trans-selective hydroboration of internal alkynes and the so-obtained products. The inventive process makes use of a borane of the formula XXBH selected from the group of dialkyl boranes or di(alkoxy)boranes which are reacted with the internal alkynes in the presence of a cyclyopentadienyl-coordinated ruthenium catalyst. 2. Process for highly stereoselective trans-hydroboration of internal alkynes according to wherein claim 1 , in formulas (I) and (II):{'sup': 1', '2, 'sub': 1', '20', '5', '8', '6', '20', '5', '20', '1', '6', '1', '6, 'Rand Rare the same or different and are each selected from straight chain or branched chain aliphatic hydrocarbons having 1 to 20 carbon atoms optionally including heteroatoms and/or aromatic hydrocarbons in the chain or aromatic hydrocarbons having 5 to 20 carbon atoms, optionally having one or more substituents selected from C-C-alkyl, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon, Cto Cheteroaromatic hydrocarbon or aryl-(C-C)-alkyl, heteroaryl-(C-C)-alkyl, or heteroatoms, or'}{'sup': 1', '2, 'sub': 1', '20', '5', '8', '6', '20', '5', '20', '1', '6', '1', '6', '1', '20', '6', '20', '5', '20', '1', '6', '1', '6, 'Rand Rtogether form an aliphatic hydrocarbon chain structure having 8 to 20 carbon atoms, optionally including heteroatoms and/or aromatic hydrocarbons in the chain and/or optionally having one or more substituents selected from C-C-alkyl, C-C-heterocycloalkyl or Cto Caromatic hydrocarbon, Cto Cheteroaromatic hydrocarbon or aryl-(C-C)-alkyl, heteroaryl-(C-C)-alkyl, said chain structure optionally being substituted by one or more substituents selected from heterosubstituents, straight chain, branched chain, cyclic aliphatic Cto Chydrocarbons, Cto Caromatic hydrocarbon, Cto Cheteroaromatic hydrocarbon, aryl-(C-C)-alkyl, or heteroaryl-(C-C)-alkyl.'}4. Process for highly stereoselective trans-hydroboration of internal alkynes according to wherein claim 3 , in the formula XXBH ...

Подробнее
23-08-2018 дата публикации

AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

Номер: US20180237415A1
Принадлежит:

The present invention relates to amide derivatives having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. 116-. (canceled)19. The compound according to claim 18 , wherein W is nitrogen and Rn is unsubstituted Calkyl.21. The compound according to claim 17 , wherein{'sub': x', 'x′, 'X is a bond, —C(RR)—, C═O or —O—; and/or'}m is 1 or 2; and/orn is 0, 1 or 2; and/orp is 0, 1 or 2.22. The compound according to claim 21 , whereinX is a bond; and/orm is 1; and/orn is 0; and/orp is 0.24. The compound according to claim 23 , whereinX is a bond;m is 1; andp is 0.26. The compound according to claim 17 , wherein{'sub': 1', '1-6', '2-6', '2-6, 'Ris selected from the group consisting of substituted or unsubstituted Calkyl, substituted or unsubstituted Calkenyl, substituted or unsubstituted Calkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl.'}27. The compound according to claim 26 , wherein Ris substituted or unsubstituted phenyl or substituted or unsubstituted pyridine.28. The compound according to claim 17 , wherein{'sub': 2', '1-6', '2-6', '2-6, 'Ris selected from hydrogen, substituted or unsubstituted Calkyl, substituted or unsubstituted Calkenyl, substituted or unsubstituted Calkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl.'}29. The compound according to claim 28 , wherein Ris substituted or unsubstituted phenyl.30. The compound according claim 17 , wherein{'sub': 3', '1-6', '2-6', '2-6', '7', '7′', '2', '7, 'Ris selected from substituted or unsubstituted Calkyl, substituted or unsubstituted Calkenyl, substituted or unsubstituted Calkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted ...

Подробнее
23-07-2020 дата публикации

ENERGY SOURCE SUPPLY SYSTEMS, ENERGY SOURCE SUPPLY DEVICES, AND RELATED METHODS

Номер: US20200230755A1
Автор: Haberman David, Mau Elaine
Принадлежит: A3 Labs LLC

Some embodiments include an energy source supply appliance. The appliance energy source supply system can comprise an appliance energy source supply subsystem, and the appliance energy source supply subsystem can comprise a pressure regulator, a first thermal control device, and a second thermal control device. The appliance energy source supply subsystem can be configured to receive a hydrogen fuel energy source and to make available the hydrogen fuel energy source to a receiver vehicle, and the receiver vehicle can comprise a drive system configured to use the hydrogen fuel energy source received by the receiver vehicle to motively power the receiver vehicle. Other embodiments of related systems, devices, and methods also are provided. 1) An energy source supply appliance comprising: a first thermal control device and a second thermal control device;', the appliance energy source supply system is configured to receive a hydrogen fuel energy source and to make available the hydrogen fuel energy source to a receiver vehicle;', 'the receiver vehicle comprises a drive system configured to use the hydrogen fuel energy source received by the receiver vehicle to motively power the receiver vehicle;', 'the appliance energy source supply system is configured so that the hydrogen fuel energy source is selectively received by one of the first thermal control device or the second thermal control device before the hydrogen fuel energy source is made available to the receiver vehicle;', 'the first thermal control device is configured to receive the hydrogen fuel energy source and to cause a first temperature reduction of the hydrogen fuel energy source when the first thermal control device receives the hydrogen fuel energy source;', 'the second thermal control device is configured to receive the hydrogen fuel energy source and to cause a second temperature reduction of the hydrogen fuel energy source when the second thermal control device receives the hydrogen fuel energy ...

Подробнее
01-09-2016 дата публикации

Dna-pk inhibitors

Номер: US20160250212A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Подробнее
01-09-2016 дата публикации

PREPARATION OF HOMOALLYLIC COMPOUNDS BY REACTION OF CYCLOPROPYLVINYL PRECURSORS WITH BRONSTEDT ACIDS

Номер: US20160251298A1
Автор: SCHROEDER Fridtjof
Принадлежит:

A method of forming homoallylic compounds 2 from cyclopropylvinyl precursors 1 in the presence of a Bronsted acid HQ 3. The method of forming a homoallylic alcohol according to claim 2 , wherein the E/Z ratio is greater than 70:30.4. The method according to claim 1 , wherein the residue R contains carbon-carbon unsaturation.6. The method according to wherein the precursor 1 is a cyclopropanated farnesene.8. The method of forming a homoallylic alcohol according to claim 3 , wherein the E/Z ratio is greater than 75:25.9. The method of forming a homoallylic alcohol according to claim 3 , wherein the E/Z ratio is greater than 80:20. The present invention is concerned with a process of preparing homoallylic compounds from cyclopropylvinyl precursors. The invention is also concerned with the use of the homoallylic compounds as useful intermediates in the preparation of flavor and fragrance ingredients.The rearrangement reaction of 1-substituted cyclopropylvinyl precursors β-1 to compounds of the structure 2 using various reaction conditions and reagents has been reported in the literatureand substituted benzenesulfonamides under Au(I)- or triflic acid-catalysis (A. Togni et al., . & 349, 1619 (2007); triethylsilane or triethoxysilane and Wilkinson's catalyst (I. P. Beletskaya et al., 3, 7901, 1995); ethyl propiolate and diphenyl diselenide (A. Ogawa et al., 65, 7682, 2000); Wilkinson's catalyst in dichloromethane or chloroform (R. I. Khusnutdinov et al., 1373, 1991) and trimethylsilyl halides (W-D. Z. Li, J-H. Yang, 6, 1849, 2004) have been used for this transformation.In all these examples, however, relatively expensive and/or hazardous reactants are used, which are problematic for use on an industrial scale. Furthermore, relatively high amounts (10%) of expensive catalysts such as Au(I), Ag(I), triflic acid, Rh(I) or stoichiometric amounts of additives such as diphenyl diselenide are necessary.Accordingly, the invention provides in a first aspect a method of forming ...

Подробнее
30-08-2018 дата публикации

QUINOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF

Номер: US20180244695A1
Автор: ZHANG Ruling
Принадлежит:

Disclosed are a quinoline derivative, and a pharmaceutical composition, a preparation method and a use thereof. The quinoline derivative of the present invention has a c-Met inhibitory activity and can be used for the treatment, relieving and/or prevention of cancers or similar diseases. 2. The quinoline derivative claim 1 , the tautomer claim 1 , the mesomer claim 1 , the racemate claim 1 , the enantiomer claim 1 , the diastereomer claim 1 , or the pharmaceutically acceptable salt thereof according to claim 1 , wherein claim 1 ,{'sub': 1', '3', '1-3, 'sup': a', 'b, 'in the definition of R, R, R, R, substituted 5-6 membered heteroaryl and substituted 9-10 membered heteroaryl, the Calkyl is independently selected from methyl, ethyl, or isopropyl;'}{'sub': 3', '1-3, 'and/or, in the definition of substituted 5-6 membered heteroaryl, Rand substituted 9-10 membered heteroaryl, the Calkoxy is independently selected from methoxy, ethoxy, or isopropoxy;'}{'sub': '3', 'sup': a', 'b, 'and/or, in the definition of R, Rand R, the halogen is independently selected from fluorine, chlorine, bromine, or iodine;'}and/or, the 5-6 membered heteroaryl is pyrazolyl or imidazolyl;and/or, the 9-10 membered heteroaryl is a 9-10 membered heteroaryl containing 4 nitrogen atoms;and/or, the carbon atom in the 5-6 membered heteroaryl links to Q ring;and/or, the carbon atom in the 9-10 membered heteroaryl links to Z;and/or, when the 5-6 membered heteroaryl is substituted, the substituted position is at heteroatom;and/or, when the 9-10 membered heteroaryl is substituted, the substituted position is at carbon atom.4. The quinoline derivative claim 1 , the tautomer claim 1 , the mesomer claim 1 , the racemate claim 1 , the enantiomer claim 1 , the diastereomer claim 1 , or the pharmaceutically acceptable salt thereof according to claim 1 , wherein claim 1 ,the 9-10 membered heteroaryl is a fused ring or a ring system having two rings sharing one bond;and/or, when the 9-10 membered heteroaryl ...

Подробнее
31-08-2017 дата публикации

HIGH TEMPERATURE ISOMERIZATION OF (E)-1-CHLORO-3,3,3-TRIFLUOROPROPENE TO (Z)-1-CHLORO-3,3,3-TRIFLUOROPROPENE

Номер: US20170247304A1
Принадлежит:

Disclosed are processes for a high temperature isomerization reaction converting (E)-1-chloro-3,3,3-trifluoropropene to (Z)-1-chloro-3,3,3-trifluoropropene. In certain aspects of the invention, such a process includes contacting a feed stream with a heated surface, where the feed stream includes (E)-1-chloro-3,3,3-trifluoropropene or mixture of (E)-1-chloro-3,3,3-trifluoropropene with (Z)-1-chloro-3,3,3-trifluoropropene. The resulting product stream includes (Z)-1-chloro-3,3,3-trifluoropropene and (E)-1-chloro-3,3,3-trifluoropropene, where the ratio of (Z) isomer to (E) isomer in the product stream is higher than the ratio feed stream. The (E) and (Z) isomers in the product stream may be separated from one another. 1. A method of converting (E)1-chloro-3 ,3 ,3-trifluoropropene into (Z)1-chloro-3 ,3 ,3-trifluoropropene , comprising:providing a reaction mixture comprising (E)1-chloro-3,3,3-trifluoropropene and, optionally, (Z)-1-chloro-3,3,3-trifluoropropene;heating said reaction mixture to temperature of greater than 400° C. for a period of time and under conditions effective to form a product mixture comprising a concentration of (Z)1-chloro-3,3,3-trifluoropropene that is greater than that provided in the reaction mixture.2. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 550° C.3. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 500° C.4. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 475° C.5. The method of claim 1 , wherein said reaction mixture is heated to a temperature from greater than 400° C. to about 450° C.6. The method of claim 1 , further comprising the step of providing a temperature controlled reaction vessel that includes an interior surface claim 1 , a first opening claim 1 , a second opening claim 1 , a pathway fluidly connecting the first and ...

Подробнее
17-09-2015 дата публикации

PREPARATION OF GGA AND DERIVATIVES THEREOF AND THEIR CO-CRYSTALLIZATION WITH UREA OR THIOUREA

Номер: US20150258039A1
Принадлежит: COYOTE PHARMACEUTICALS, INC.

Provided herein are compositions comprising co-crystals of GGA or a GGA derivative (including salts and tauotomers thereof) with urea or thiourea, and processes related to such co-crystals. Also provided herein are methods, compounds, and compositions related to preparing trans GGA and derivatives thereof, and intermediates thereto. 1. A co-crystal or co-precipitate comprising GGA , geranylgeranyl alcohol , or another GGA derivative , and urea and/or thiourea , wherein the GGA , geranylgeranyl alcohol , or the another GGA derivative exists at least 80% , or at least 90% , or at least 95% , or at least 99% in the trans isomer.2. The co-crystal or co-precipitate of admixed with a composition comprising GGA claim 1 , geranylgeranyl alcohol claim 1 , or the other GGA derivative claim 1 , wherein the GGA claim 1 , geranylgeranyl alcohol claim 1 , or the another GGA derivative in the composition exists substantially less in the trans form compared to the GGA claim 1 , geranylgeranyl alcohol claim 1 , or the another GGA derivative that is complexed as part of the co-crystal or the co-precipitate.3. The co-crystal or co-precipitate of claim 1 , which is crystalline.4. A crystalline GGA derivative existing in the trans form or substantially in the trans form.5. A process of preparing a co-crystal or a co-precipitate of GGA claim 1 , geranylgeranyl alcohol claim 1 , or another GGA derivative claim 1 , and urea and/or thiourea claim 1 , wherein the GGA claim 1 , geranylgeranyl alcohol claim 1 , or the another GGA derivative exists at least 80% claim 1 , or at least 90% claim 1 , or at least 95% claim 1 , or at least 99% as the trans isomer claim 1 , the process comprising contacting a mixture of cis and trans isomers of GGA claim 1 , geranylgeranyl alcohol claim 1 , or the another GGA derivative with a composition comprising urea and/or thiourea under conditions sufficient to form the co-crystal or the co-precipitate claim 1 , to provide the co-crystal or the co-precipitate.6. ...

Подробнее
08-08-2019 дата публикации

METHOD FOR ISOMERIZING ORGANIC COMPOUND, AND METHOD FOR PRODUCING ISOMER OF ORGANIC COMPOUND

Номер: US20190241490A1
Принадлежит: AGC Inc.

A useful evaluation method which enables highly efficient production of a partially fluorinated alumina having good catalytic activities is discovered, and a method for isomerizing an organic compound whereby it becomes possible to improve a conversion rate in the desired isomerization reaction is provided. The method for isomerizing an organic compound comprises a step of selecting an alumina so that the acid amount calculated from the amount of ammonia desorbed at a desorption temperature of at least 300° C. by temperature-programmed desorption of ammonia is at least 0.10 mmol/g and at most 0.25 mmol/g; a step of fluorinating the selected alumina by a fluorinating agent to produce a partially fluorinated alumina; and a step of isomerizing, by using the obtained partially fluorinated alumina, an organic compound having at least two carbon atoms wherein to at least one of the adjacent carbon atoms, at least one fluorine atom is bonded and to the other, at least one chlorine atom or hydrogen atom is bonded. 1. A method for isomerizing an organic compound , characterized by comprisinga step of selecting an alumina, so that the acid amount calculated from the amount of ammonia desorbed at a desorption temperature of at least 300° C. by temperature programmed desorption of ammonia is at least 0.10 mmol/g and at most 0.25 mmol/g,a step of fluorinating the selected alumina by a fluorinating agent to obtain a partially fluorinated alumina, anda step of isomerizing, by using the obtained partially fluorinated alumina, an organic compound having at least two carbon atoms, wherein to at least one of the adjacent carbon atoms, at least one fluorine atom is bonded and to the other, at least one chlorine atom and/or hydrogen atom is bonded.2. The method for isomerizing an organic compound according to claim 1 , wherein the alumina is an alumina having a γ-AlOstructure.3. The method for isomerizing an organic compound according to claim 1 , wherein the fluorinating agent is the ...

Подробнее
07-09-2017 дата публикации

Graphene-Based Inorganic-Organic Hybrid Materials and Separation of Racemic Mixtures

Номер: US20170253489A1
Принадлежит: STC.UNM

A variety of inorganic-organic hybrid materials and various methods for preparing and using the same are described. The hybrid materials are graphene or graphitic materials populated with organic molecules and may have a variety of surface defects, pits or three-dimensional architecture, thereby increasing the surface area of the material. The hybrid materials may take the form of three dimensional graphene nanosheets (3D GNS). If the organic molecules are enantiospecific molecules, the hybrid materials can be used for chiral separation of racemic mixtures. 1. A method for chiral separation of racemic mixtures comprising:providing a column containing an enantioselective two- or three-dimensional graphene or graphitic material;flowing a racemic mixture through the column such that first and second enantiomers in the racemic mixture encounter the enantioselective two- or three-dimensional graphene or graphite and are separated thereby.2. The method of wherein the two- or three-dimensional graphene or graphitic material is populated with enantioselective organic molecules.3. The method of wherein the two- or three-dimensional material is a two-or three-dimensional graphene nanosheet.4. The method of comprising a three dimensional graphene nanosheet wherein the three dimensional graphene nanosheet is a non-contiguous three dimensional graphene material comprising graphene walls and voids.5. The method of wherein the non-contiguous three dimensional graphene material comprising graphene walls and voids is disordered.6. The method of claim wherein the racemic mixture is ibuprofen and the enantioselective molecule is (S)-(+)-2-pyrrolidinemethanol.7. An apparatus for chiral separation of racemic mixtures claim 4 , the apparatus comprising a column containing enantioselective two- or three-dimensional graphene or graphitic material.8. The apparatus of wherein the two- or three-dimensional graphene or graphitic material is populated with enantioselective organic molecules.9. ...

Подробнее
07-09-2017 дата публикации

Terminal Conjugated Trienal Acetal Compound and Method for Producing Terminal Conjugated Trienal Compound Using the Same

Номер: US20170253548A1
Принадлежит:

Provided are a terminal conjugated trienal acetal compound useful as an intermediate for producing a terminal conjugated trienal compound, and a method for producing a terminal conjugated trienal compound through deprotection of the terminal conjugated trienal acetal compound. More specifically, provided are a terminal conjugated trienal acetal compound represented by General Formula (1); a method for producing a (Z,E)-terminal conjugated trienal acetal compound, the method comprising the step of: reacting a phosphonium salt represented by General Formula (7) with (E)-2,4-pentadienal through Wittig reaction to obtain a (Z,E)-terminal conjugated trienal acetal compound represented by General Formula (3); and a method for producing a terminal conjugated trienal compound, the method comprising the step of: deprotecting the terminal conjugated trienal acetal compound represented by General Formula (1) to obtain a terminal conjugated trienal compound represented by General Formula (2). 1. Field of the InventionThe present invention relates to a terminal conjugated trienal acetal compound useful as an intermediate for synthesis of an insect sex pheromone and to a method for producing a terminal conjugated trienal compound through deprotection of the terminal conjugated trienal acetal compound.2. Description of the Related ArtInsect sex pheromones are the biologically active substances which are commonly secreted by female insects and have the function of attracting male insects. A small amount of a sex pheromone shows strong attractive activities. Sex pheromones have been widely used as means for forecasting insect emergence or for ascertaining regional spread (invasion into a specific region) and as means for controlling insect pests. As the means for controlling insect pests, control methods such as mass trapping, lure-and-kill or attract-and-kill, lure-and-infect or attract-and-infect, and mating disruption are widely used in practice. To utilize a sex pheromone, ...

Подробнее
30-09-2021 дата публикации

MODULATORS OF ROR-GAMMA

Номер: US20210300869A1
Принадлежит:

Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Such derivatives include e.g., those having the Formula II. 125-. (canceled)28. The compound of claim 27 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 27 , wherein Lis CH claim 27 , CH(CH) claim 27 , O claim 27 , or C(O).30. The compound of claim 29 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 29 , wherein Ris H claim 29 , (C-C)alkyl claim 29 , (C-C)alkylOH claim 29 , —(C-C)alkylNH claim 29 , —(C-C)alkyl-N-di(C-C)alkyl claim 29 , or —O(C-C)alkyl-C(O)—NH; and Ris hydrogen.31. The compound of claim 30 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 30 , wherein Ris (C-C)OH.32. The compound of claim 31 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 31 , wherein Ris (C-C)alkyl or cyclopropyl.33. The compound of claim 32 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 32 , wherein Cyis aryl or heteroaryl claim 32 , each substituted with 1 to 3 groups independently selected from R.34. The compound of claim 33 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 33 , wherein Cyis phenyl or pyridyl claim 33 , each substituted with 1 to 3 groups independently selected from R.35. The compound claim 34 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 34 , wherein at least 1 Ris S(O)(C-C)alkyl.36. The compound of claim 35 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 35 , wherein Cyis pyridyl substituted with 1 to 3 groups independently selected from R claim 35 , wherein at least 1 Ris S(O)(C-C)alkyl.37. The compound of claim 35 , or a pharmaceutically acceptable salt or stereoisomer thereof claim 35 , wherein Cyis phenyl claim 35 , pyridyl claim 35 , cyclohexyl claim 35 , tetrahydropyranyl claim 35 , ...

Подробнее
13-09-2018 дата публикации

Energy source supply systems, energy source supply devices, and related methods

Номер: US20180257504A1
Автор: David Haberman, Tyler Elm
Принадлежит: A3 Labs LLC

Some embodiments include an energy source supply appliance. The energy source supply appliance can comprise an appliance energy source supply system, which in turn can comprise a first appliance energy source supply subsystem and a second appliance energy source supply subsystem. The first appliance energy source supply subsystem can be configured to receive a first energy source. Meanwhile, the second appliance energy source supply subsystem can be configured to make available a second energy source to a first receiver vehicle, and the second energy source can be different from the first energy source. Further, the first receiver vehicle can comprise a first drive system, and the first drive system can be configured to use the second energy source received by the first receiver vehicle to motively power the first receiver vehicle. Other embodiments of related systems, devices, and methods also are provided.

Подробнее
14-10-2021 дата публикации

HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER

Номер: US20210317127A1
Принадлежит:

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R, L, L, L, A, A, A, A, G, G, E, W, X, Y, Z, m, and n are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. 4. The compound of any one of - , wherein R′ is H , m is 2 and at least one occurrence of X , Y and Z is CRwherein Ris not H or at least one occurrence of X , Y and Z is NRwherein Ris not H.5. The compound of any one of - , wherein X is N , Y is CRand Z is CR.6. The compound of any one of - , wherein X is CR , Y is CRand Z is N.7. The compound of any one of - , wherein X is CR , Y is N and Z is CR.8. The compound of any one of - , wherein X is N , Y is CRand Z is N.9. The compound of any one of - , wherein X is N , Y is N and Z is CR.10. The compound of any one of - , wherein X is CR , Y is N and Z is N.11. The compound of any one of - , wherein X is NR , Y is CRand Z is N.12. The compound of any one of - , wherein X is N , Y is CRand Z is NR.13. The compound of any one of - , wherein X is CR , Y is NRand Z is N.14. The compound of any one of - , wherein X is CR , Y is NRand Z is CR.15. The compound of any one of - , wherein X is NR , Y is CRand Z is CR.16. The compound of any one of - , wherein R′ is H , m is 2 and X , Y and Z are each , independently , CH or N , provided that at least one of at least one of X , Y and Z is N.17. The compound of claim 16 , wherein X is N claim 16 , Y is CH and Z is CH.18. The compound of claim 16 , wherein X is CH claim 16 , Y is N and Z is CH.19. The compound of claim 16 , wherein X is CH claim 16 , Y is CH and Z is N.20. The compound of claim 16 , wherein X is N claim 16 , Y is N and Z is CH.21 ...

Подробнее
13-09-2018 дата публикации

SYNTHESIS OF PARACETAMOL (ACETOMINOPHEN) FROM BIOMASS-DERIVED P-HYDROXYBENZAMIDE

Номер: US20180258030A1
Принадлежит:

Disclosed is a method to make N-acetyl-p-aminophenol. The method includes steps for converting biomass-derived p-hydroxybenzoates to p-hydroxybenzamide, then to p-aminophenol; and then N-acetylating the p-aminophenol. 1. A method to make N-acetyl-p-aminophenol , the method comprising:(a) converting p-hydroxybenzamide to p-aminophenol; and then(b) N-acetylating at least a portion of the p-aminophenol to yield N-acetyl-p-aminophenol.2. The method of claim 1 , wherein claim 1 , step (a) comprises contacting the p-hydroxybenzamide with a hypohalite salt to cause a Hofmann-style rearrangement reaction claim 1 , thereby yielding p-aminophenol.3. The method of claim 1 , wherein step (b) comprises contacting the p-aminophenol with acetic anhydride and water for a time and at a temperature to yield N-acetyl-p-aminophenol.4. The method of claim 1 , wherein claim 1 , step (a) comprises contacting the p-hydroxybenzamide with a hypohalite salt to cause a Hofmann-style rearrangement reaction claim 1 , thereby yielding p-aminophenol; andstep (b) comprises contacting the p-aminophenol with acetic anhydride and water for a time and at a temperature to yield N-acetyl-p-aminophenol.5. The method of claim 4 , wherein step (a) is conducted in an alkaline aqueous or non-aqueous solvent claim 4 , at a pH from about 10 to about 14 claim 4 , a temperature from about 20° C. to about 100° C. claim 4 , and for a time of from about 30 minutes to about 24 h.6. The method of claim 4 , wherein step (b) is conducted at a temperature of from about 100° C. to about 150° C.7. The method of claim 4 , wherein step (a) is conducted in an alkaline aqueous or non-aqueous solvent claim 4 , at a pH from about 10 to about 14 claim 4 , a temperature from about 20° C. to about 100° C. claim 4 , and for a time of from about 30 minutes to about 24 h; andstep (b) is conducted at a temperature of from about 100° C. to about 150° C.8. A method to make N-acetyl-p-aminophenol claim 4 , the method comprising:(a) ...

Подробнее
01-10-2015 дата публикации

Metathesis Catalysts Containing Onium Groups

Номер: US20150274763A1
Принадлежит: Apeiron Synthesis Sp zoo

Disclosed herein is a general method for the preparation of complexes containing a quaternary onium group in an inert ligand. Some of these complexes may be represented by formula 1: Methods for the preparation of complexes of formula 1, the preparation of intermediates and the use of complexes of formula 1 in metathesis reactions and a method for conducting an olefin metathesis reaction are also described.

Подробнее
22-08-2019 дата публикации

Vitamin D Compounds and Methods for Preparing Same

Номер: US20190254312A1
Принадлежит:

An air-stable, high-melt 1a-hydroxy-vitamin Dcompound, methods for preparing an animal feed composition, methods of preparing 1a-hydroxy-vitamin D, methods of enhancing phytate phosphorus and calcium utilization, and an animal feed regime are provided. 129-. (canceled)30. A method for preparing 1α-hydroxy-vitamin Dcomprising the steps oftreating vitamin D3 with sulfur dioxide to produce two cyclic compounds, each protected via a silicon-protecting group;{'sub': '3', 'rearranging the silicon-protecting group compounds with sulfur dioxide extrusion via thermal isomerization to yield a silicon-protected 5,6-trans-vitamin D;'}{'sub': '3', 'oxidizing 5,6-trans-vitamin Dvia allylic oxidation to yield a 1α-hydroxy derivative;'}{'sub': '3', 'de-protecting the 1α-hydroxy derivative to yield crystalline 1α-hydroxy-5,6-trans-vitamin D; and'}{'sub': 3', '3', '3, 'photochemically isomerizing the crystalline 1α-hydroxy-5,6-trans-vitamin Dto yield 1α-hydroxy-vitamin D, wherein the 1α-hydroxy-vitamin Dhas a melting point of about 140° C. to about 144° C.'}31. The method of claim 30 , further comprising the steps of purifying the 1α-hydroxy-vitamin Dvia polish filtration and recrystallizing the 1α-hydroxy-vitamin Dvia a solvent exchange with at least one solvent selected from the group consisting of n-heptane claim 30 , heptanes claim 30 , and a combination thereof.32. The method of claim 31 , wherein the at least one solvent is n-heptane.33. The method of claim 30 , wherein the 1α-hydroxy-vitamin Dis 1α claim 30 ,3β claim 30 ,5Z claim 30 ,7E-9 claim 30 ,10-secocholesta-5 claim 30 ,7 claim 30 ,10(19)-triene-1 claim 30 ,3-diol.34. The method of claim 30 , further comprising the steps of drum-drying or spray-drying the 1α-hydroxy-vitamin Dand mixing the 1α-hydroxy-vitamin Dwith a carrier.35. The method of claim 30 , wherein the yield of 1α-hydroxy-5 claim 30 ,6-trans-vitamin Dis at least about 30%.36. The method of claim 30 , further comprising the steps of dissolving the 1α-hydroxy-5 ...

Подробнее
04-12-2014 дата публикации

METHODS FOR STEREOSELECTIVE REDUCTION

Номер: US20140357868A1
Принадлежит: INFINITY PHARMACEUTICALS, INC.

The invention is directed to a method to reduce a C—C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product, comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine. 1. A method of reducing the C—C double bond of an enone of a steroidal compound to produce a mixture of β ketone product and α ketone product , the method comprising treating a solution or suspension of the steroidal compound in a solvent with hydrogen gas in the presence of a catalyst and a substituted pyridine.2. The method of claim 1 , wherein an excess of the β ketone product is produced compared to the α ketone product.3. The method of claim 1 , wherein the ratio of the β ketone product to the α ketone product is at least 2:1.4. The method of claim 1 , wherein the ratio of the β ketone product to the α ketone product is at least 10:1.5. The method of claim 1 , wherein the ratio of the P ketone product to the α ketone product is at least 20:1.6. The method of claim 1 , wherein the ratio of the β ketone product to the α ketone product is at least 50:1.7. The method of claim 1 , wherein the substituted pyridine is a 3-substituted pyridine.8. The method of claim 7 , wherein the 3-substituted pyridine is selected from 3-picoline claim 7 , 3-methoxypyridine claim 7 , 3-ethylpyridine claim 7 , 3-n-butylpyridine claim 7 , 3-isobutylpyridine claim 7 , 3-hydroxypyridine claim 7 , 3-aminopyridine claim 7 , and 3-dimethylaminopyridine.9. The method of claim 7 , wherein the 3-substituted pyridine is 3-picoline.10. The method of claim 1 , wherein the catalyst is a palladium catalyst.11. The method of claim 1 , wherein the solvent comprises the substituted pyridine.12. The method of claim 11 , wherein the solvent comprises 3-picoline.14. The method of claim 13 , wherein an excess of the compound of formula II is produced compared to the compound of formula ...

Подробнее